

BMJ Open

Changes in psychosocial and physical working conditions and subsequent psychotropic medication in ageing public sector employees

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015573
Article Type:	Research
Date Submitted by the Author:	16-Dec-2016
Complete List of Authors:	Kouvonen, Anne; University of Helsinki, Social Research; SWPS University of Social Sciences and Humanities, Faculty in Wroclaw Mänty, Minna; Helsinki University, Department of Public Health Lallukka, Tea; Finnish Institute of Occupational Health, Lahelma, Eero; University of Helsinki, Department of Public Health Rahkonen, Ossi; University of Helsinki, Department of Public Health
Primary Subject Heading:	Occupational and environmental medicine
Secondary Subject Heading:	Epidemiology
Keywords:	MENTAL HEALTH, longitudinal studies, work stress

SCHOLARONE™
Manuscripts

Changes in psychosocial and physical working conditions and subsequent psychotropic medication in ageing public sector employees

Anne Kouvonen,^{1,2,3} Minna Mänty,⁴ Tea Lallukka,^{4,5} Eero Lahelma,⁴ Ossi Rahkonen⁴

¹Faculty of Social Sciences, University of Helsinki, Helsinki, Finland

²SWPS University of Social Sciences and Humanities in Wroclaw, Wroclaw, Poland

³Administrative Data Research Centre (Northern Ireland), Centre for Public Health, Queen's University Belfast, Belfast, UK

⁴Department of Public Health, University of Helsinki, Helsinki, Finland

⁵Finnish Institute of Occupational Health, Helsinki, Finland

*Address for correspondence: Dr Anne Kouvonen, Department of Social Research, P.O. Box 54, 00014 University of Helsinki, Finland.

Telephone: +358 50 4487113; Email: anne.kouvonen@helsinki.fi

Manuscript statistics: 240 words in Abstract, 2989 words in text, 39 references, 3 tables

Funding

This work was supported by the Finnish Work Environment Fund (grant 112231), the Academy of Finland (grants 1129225, 1257362, 1294514) and the University of Helsinki. AK was supported by the Economic and Social Research Council (ESRC) (grant ES/L007509/1). MM was supported by the Finnish Work Environment Fund (grant 115182) and the Juho Vainio Foundation. TL was supported by the Academy of Finland (grant 287488).

Abstract

Objectives: To investigate whether changes in psychosocial and physical working conditions are associated with subsequent psychotropic medication in ageing employees.

Methods: Data were from the Helsinki Health Study, a cohort study of Finnish municipal employees, aged 40-60 years at Phase 1 (2000-2002). Changes in psychosocial and physical working conditions were measured between Phase 1 and Phase 2 (2007). Survey data were longitudinally linked to data on prescribed, reimbursed psychotropic medication purchases (ATC) obtained from the registers of the Social Insurance Institution of Finland between the Phase 2 survey and December 2013 (N=3587; 80% women). Outcomes were any psychotropic medication; antidepressants (N06A); anxiolytics (N05B); and sedatives and hypnotics (N05C). Cox regression analyses were performed.

Results: During the follow-up 28% of the participants were prescribed psychotropic medication. Repeated exposures to low job control, high job demands and high physical work load were associated with an increased risk of subsequent antidepressant and anxiolytic medication. Increased and repeated exposure to high physical work load, increased job control and repeated high job demands were associated with subsequent sedative and hypnotic medication. Age and sex adjusted hazard ratios varied from 1.18 to 1.66. Improvement in job control was associated with a lower risk of anxiolytic, but with a higher risk of sedatives and hypnotic medication. Decreased physical work load was associated with a lower risk of antidepressant and anxiolytic medication.

Conclusion: Improvement in working conditions could lower the risk of mental ill-health indicated by psychotropic medication.

Keywords: mental health; longitudinal studies; work stress

1
2
3 **Abbreviations:** ATC, Anatomical Therapeutic Chemical; BMI, body mass index; CI, confidence
4 interval; DDD, defined daily dose; HR, hazard ratio; WHO, World Health Organization
5
6
7
8
9

10 **Strengths and limitations of this study**

- 13 • Unlike previous studies, we were able to examine changes in both psychosocial and physical
14 working conditions.
- 15 • Data were derived from a well characterised occupational cohort which was
16 deterministically linked to administrative medication records.
- 17 • The use of register-based medication data allowed us to remove the prevalent cases and
18 helped avoid the problems related to use of self-report measures such as recall and common
19 method bias.
- 20 • Due to relatively long interval between the two working conditions measurements, the study
21 could have underestimated the effect of changing working conditions on subsequent
22 psychotropic medication.
- 23 • We did not have information about clinical indication the examined medication was
24 prescribed for.
- 25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Mental ill-health is a growing concern in working populations.[1] Adverse working conditions have been proposed as potentially modifiable risk factors for mental ill-health.[2] Indeed, there is evidence that exposure to adverse psychosocial working conditions such as low job control and high job demands, are associated with an increased risk of mental ill-health.[3–5] However, the majority of earlier studies have measured both exposure and outcome using self-reports, which can lead to inflated associations and common method bias.[6] Other studies have avoided these problems by using register-based outcomes such as psychotropic medication, which is a commonly used marker of mental ill-health in a population.[7–12]

Most of the earlier studies have assessed exposure to adverse working conditions only at one time point, and there is a paucity of large-scale studies examining the association between changes in psychosocial working conditions and mental ill-health. Of a few studies that have separately assessed the effects of changes in job control and job demands on mental ill-health, three found that adverse changes in job demands had a stronger effect on the risk of self-reported mental ill-health than adverse changes in job control, whereas positive changes in these domains did not result in improvement in mental health.[5,13,14] In a recent study within-person increase in job control was associated with better self-reported mental health;[15] and in another study both improvements and deterioration in job demands and job control predicted change in mental health.[16] However, studies assessing the association between changes in job control and job demands and a more objective measure of mental ill-health, such as recorded psychotropic medication, are lacking.

Moreover, psychosocial working conditions have dominated discussion about the work-related determinants of poor mental health, even though there is evidence that also physical working

1
2
3 conditions are associated with mental ill-health. In the present cohort, increased and repeated
4 exposure to repetitive movements and repeated exposure to awkward postures and rotation of back
5 was associated with an increased likelihood of common mental disorders,[14] desktop work was
6 associated with purchases of sleeping pills among women,[17] and computer work was a risk factor
7 for disability retirement due to mental causes.[18] In another study deteriorating physical working
8 conditions increased perceived mental strain.[19] A review of the impact of working environment
9 on mood disorders discussed the potential mechanisms; however actual studies conducted in
10 employee cohorts were rare.[20] In a study among blue-collar workers exposure to noise intensified
11 anxiety and depression in women.[21]

12
13
14 We set out this study to examine the associations between changes in psychosocial and physical
15 working conditions and subsequent psychotropic medication.

16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

METHODS

Data

The data came from the Helsinki Health Study, which is a cohort study designed to investigate social and work-related determinants of health and well-being.[22] The target population is the staff of the City of Helsinki, Finland. Phase 1 questionnaire surveys were collected in 2000, 2001 and 2002 among employees turning 40, 45, 50, 55 or 60 each year (N=8960, response rate 67%; 80% of participants women). Phase 2 survey data were collected in 2007 (N=7332, response rate 83%). Earlier non-response analysis showed that the participants broadly represent the target population.[22] Survey data were linked to national records using a unique personal identification number for those respondents who had given written consent for the linkage (74%; N=6498).

1
2
3 Consenting for the data linkage followed a similar pattern as the non-response, except that men
4 provided consent slightly more often than women.[22,23]
5
6
7
8

9
10 In the present study, of those who consented to linkage, only participants who were still employed
11 at Phase 2 were included (N=4207). Men, manual workers and those who reported common mental
12 disorders at Phase 1 had slightly more often left the employment between the two phases (all *p*
13 values < 0.01, data not shown). Because of the age structure of the cohort, the majority (86%) of
14 those who replied at Phase 2 and stated that they were not employed, had retired.
15
16
17
18
19

20
21 In addition, we excluded those with purchases of psychotropic medication in three months
22 preceding Phase 2 (n=337 for any psychotropic medication). Finally, we excluded those participants
23 who had missing values for any of the study variables (n=283). The exclusions resulted in a final
24 analytic sample of 3587 participants for the analyses examining any psychotropic medication.
25
26
27
28
29
30
31
32
33

34 **Ethics**

35
36
37
38 The Helsinki Health Study protocol was approved by the Ethics Committees of the Department of
39 Public Health, University of Helsinki, and the health authorities of the City of Helsinki. The study
40 conformed to the principles embodied in the Declaration of Helsinki.
41
42
43
44
45
46
47

48 **Measurements**

49 **Working conditions**

50
51
52
53
54
55
56
57
58
59
60

1
2
3 We used a version of Karasek's Job Content Questionnaire[24] to measure job control and job
4 demands. Job control was assessed by nine and job demands by five items. Missing values were
5 replaced by item modes for those having responded to at least eight job control and four job
6 demands items, respectively. Job control and job demands were both dichotomised at the
7 median.[7,25]
8
9

10
11
12
13
14
15
16 *Physical work load* was assessed with an 18-item instrument developed at the Finnish Institute of
17 Occupational Health.[26] Missing values were replaced by item modes for those having responded
18 to at least fourteen items. Factor analysis showed that the questions loaded on three factors, of
19 which the first one was interpreted to best measure physical work load. The items with the largest
20 positive standardised scoring coefficients were: awkward working positions; rotation of the back;
21 repetitive movements; and heavy physical effort or lifting and carrying heavy loads. Physical work
22 load factor score was dichotomised at the highest quartile.[27]
23
24
25
26
27
28
29
30
31
32
33

34 Changes in psychosocial and physical working conditions were measured by a four-category
35 variable for each of the three exposure variables: (i) repeated low exposure (low exposure at Phase
36 1 and low exposure at Phase 2); (ii) increased exposure (low exposure at Phase 1 and high exposure
37 at Phase 2); (iii) decreased exposure (high exposure at Phase 1 and low exposure at Phase 2); (iv)
38 repeated high exposure (high exposure at Phase 1 and high exposure at Phase 2).[28]
39
40
41
42
43
44
45
46

47 **Psychotropic medication**

48
49
50

51
52 Data on psychotropic medication were derived from the Finnish Prescription Register. This register
53 is maintained by the Social Insurance Institution and it includes records of all prescribed
54 psychotropic medication purchases reimbursed to Finnish residents in non-institutional settings. For
55
56
57
58
59
60

1
2
3 each dispensed drug, the record includes the dispensing date, the WHO Anatomical Therapeutic
4 Chemical (ATC) code, and the quantity prescribed and purchased as the number of defined daily
5 doses (DDDs).[29] We extracted information on all purchases of antidepressants, anxiolytics,
6
7 sedatives and hypnotics (ATC-codes N06A, N05B and N05C, respectively) in our analytic sample,
8
9 following Phase 2 survey date (index date) during the follow-up until December 31, 2013. Dates of
10
11 deaths were retrieved from Statistics Finland (the Causes of Death Register).
12
13
14
15
16
17

18 **Covariates**

19
20
21 All covariates were survey-based and from Phase 1. We measured age, sex and marital status
22
23 (married/cohabiting vs. other). Moreover, we measured current smoking (yes vs. no), binge
24
25 drinking (six or more units of alcohol on one occasion once a month or more often), low physical
26
27 activity (less than 14 metabolic equivalent hours per week) and body mass index, which was
28
29 categorised as non-obese ($\leq 30 \text{ kg/m}^2$) and obese ($>30 \text{ kg/m}^2$).
30
31
32
33
34
35

36 **Statistical analysis**

37
38
39 The associations between sex, age and psychotropic medication during the follow-up were first
40
41 analysed using the Chi-square test. Cox proportional hazard models were fitted to examine the
42
43 association between change in psychosocial and physical working conditions between Phase 1 and
44
45 Phase 2 and subsequent psychotropic medication during the follow-up. We estimated hazard ratios
46
47 (HRs) and their 95% confidence intervals (95% CIs) for psychotropic medication by changes in
48
49 each working condition by first controlling for age and sex; then further controlling for marital
50
51 status, smoking, binge drinking, low physical activity, and obesity. In the first analysis, for each
52
53 working condition, the reference group was the most favourable working condition (i.e. repeated
54
55 high control, repeated low demands, and repeated high physical work load, respectively). To
56
57
58
59
60

1
2
3 examine the effects of positive changes in working conditions, we conducted an additional analysis
4 using the least favourable working condition as the reference group. The follow-up began from the
5 date of the Phase 2 survey response and ended at the first record of the psychotropic medication
6 purchase, death, or on 31 December, 2013, whichever came first.
7
8
9

10
11
12 The interaction terms between each working condition and logarithm of the follow-up period for
13 any psychotropic medication as well as for each medication group were non-significant, confirming
14 that the proportional-hazards assumption was justified (all $p > 0.05$).
15
16
17

18
19
20 None of the gender interactions were statistically significant (all interaction terms sex*working
21 condition $p > 0.05$); we therefore analysed women and men together, adjusting for gender.
22
23
24

25
26
27 All analyses were conducted with the statistical program package SAS 9.4 (SAS Institute, Inc.,
28 Cary, North Carolina).
29
30
31

32 33 34 35 RESULTS

36
37
38
39 **Table 1** shows the distribution of the key study variables by any prescribed psychotropic
40 medication during follow-up. The mean age at baseline was 47.5 years. A total of 1008 participants
41 (28%) recorded at least one purchase of prescribed psychotropic medication during the mean
42 follow-up of 5.0 years. Psychotropic medication was more prevalent among women (29%) than
43 among men (23%). Nineteen percent of the participants received antidepressant medication during
44 the follow-up. The corresponding figures for anxiolytics and for hypnotics/sedatives were 7% and
45 17%, respectively.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 As displayed in **Table 2**, after adjustment for age and sex, repeated high job demands (HR=1.22,
4 95% CI: 1.04-1.42) were associated with any psychotropic medication. The association between
5 repeated high physical work load and any psychotropic medication was marginally statistically
6 significant (HR=1.17, 95% CI: 0.98-1.39).
7
8
9

10
11
12 When the groups of psychotropic medication were examined separately, repeated high job demands
13 (HR=1.20, 95% CI: 1.00-1.45) and repeated high physical work load (HR=1.30, 95% CI: 1.06-1.59)
14 were associated with subsequent antidepressant medication, whereas repeated low job control (1.37,
15 95% CI: 1.05-1.79), repeated high demands (HR=1.33, 95% CI: 1.00-1.76), and repeated high
16 physical work load (HR=1.66, 95% CI: 1.24-2.23) were associated with subsequent anxiolytic
17 medication. Increased job control and increased physical work load were associated with
18 subsequent sedative and hypnotic medication. Repeated high demands and repeated physical work
19 load showed associations with subsequent sedative and hypnotic medication. Further adjustment for
20 marital status, health behaviours, and obesity only marginally changed the HRs (data not shown).
21
22
23
24
25
26
27
28
29
30
31
32

33 We additionally tested whether favourable change in working conditions was associated with a
34 lower risk of psychotropic medication, by using the least favourable working conditions as
35 reference categories (Table 3). Compared to repeatedly low job control, increased job control was
36 associated with a lower risk of anxiolytic, but a higher risk of sedative and hypnotic medication.
37 Compared to repeatedly high physical work load, decreased physical load was associated with a
38 lower risk of subsequent antidepressant and anxiolytic medication.
39
40
41
42
43
44
45
46
47
48
49

50 DISCUSSION

51
52
53
54
55 In this study, repeated and increased exposure to adverse psychosocial and physical working
56 conditions was associated with subsequent psychotropic medication. It is notable that we found
57
58
59
60

1
2
3 similar associations for both types of working conditions. However, the associations between
4
5 adverse working conditions and subsequent psychotropic medication were modest. This is expected:
6
7 the aetiology of mental disorders – the main indication for psychotropic medication - is complex
8
9 and multifactorial, involving multiple social, psychological and biological factors.[30] Exposure to
10
11 adverse working conditions or a positive or negative change in them is only one such factor.
12
13

14
15
16 Compared to employees with repeated low job demands, the employees whose job demands had
17
18 increased had a higher risk of purchasing any psychotropic medication as well as antidepressant
19
20 medication. Antidepressant medication is likely to reflect depression and other mental disorders. A
21
22 number of previous studies have shown a link between high job demands and an increased risk of
23
24 mental ill-health.[13,14,31]
25
26

27
28
29 Previous results for job control have been mixed. Null results have been reported,[32] whereas one
30
31 previous study showed an association between high decision authority and an elevated risk of
32
33 hospital admissions due to mental disorders.[33] In our study increased job control was associated
34
35 with a subsequent sedative and hypnotic medication. In a previous study, active jobs, that is, those
36
37 with high levels of control and demands, were associated with a higher risk of depression and
38
39 burnout.[34] It is possible that increased decision authority and high responsibility may become a
40
41 burden for some employees. It is also possible that high job control reflects not only working
42
43 conditions but also characteristics of a generally more active employee with a higher likelihood of
44
45 seeking treatment.[33]
46
47
48
49

50
51
52 When comparing to the least favourable working conditions, increased job control was associated
53
54 with a lower risk of anxiolytic medication; and decreased physical load was associated with a lower
55
56 risk of antidepressant and anxiolytic medication. Two earlier studies did not find an association
57
58
59
60

1
2
3 between favourable changes in psychosocial working conditions and a decreased risk of subsequent
4 mental ill-health.[13,35] However, in one previous study both improvements and deterioration in
5 job demands and control were associated with corresponding improvements or deterioration in
6 mental health,[16] and in another study decrease of job strain was associated with a lower
7 likelihood of repeated insomnia symptoms.[36]
8
9

10
11
12 Most of the earlier studies have investigated only psychosocial working conditions. In the present
13 study repeatedly high and increased physical work load were associated with subsequent
14 psychotropic medication. In fact, the strongest association (HR=1.66 for anxiolytic medication)
15 between working conditions and psychotropic medication was found for repeated high physical
16 workload. Our findings thus support the earlier findings in the present and other cohorts, which
17 have shown associations between exposure to adverse physical working conditions and common
18 mental disorders,[14] disability retirement due to mental disorders,[18] purchases of sleeping
19 pills,[17] and perceived mental strain.[19]
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 **Methodological considerations**

37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Certain limitations need to be acknowledged. First, because of the relatively long interval between
the two working conditions measurements, this study could have underestimated the effect of
changing working conditions on subsequent medication. Moreover, working conditions could have
changed several times during the follow-up; this could have resulted in more conservative effect
sizes.

Second, we were unable to assess the magnitude of change in working conditions; the use of these
crude measures only assessed whether a participant had moved from one category to another.

Furthermore, we did not have information about the prior duration of exposure to adverse working

1
2
3 conditions. The use of thresholds may have led to underestimates of true effects of changing
4
5 working conditions.[5]
6
7

8
9
10 Third, we did not have information about clinical indication the examined medication was
11 prescribed for. Even if psychotropic medication is a recommended treatment for a number of mental
12 disorders and prescription data derived from official registers can therefore be considered as a proxy
13 for mental disorders requiring treatment, these medications are prescribed also for other conditions.
14
15 On the other hand, it has been shown that mental disorders are underdiagnosed and
16
17 undertreated.[37]
18
19
20
21
22
23

24
25 Fourth, participants who left employment between Phase 1 and Phase 2 were not included in the
26 study. It has been suggested that the age-related health selection may result in a more resilient older
27 worker population [35]. A healthy worker effect may thus have led to underestimation of the
28
29 associations.
30
31
32
33

34
35
36 Finally, even if the data consisted of a broad range of both manual and non-manual occupations, the
37 study population was not a representative sample of the total working population. Because the
38 Finnish public sector workforce is female-dominated, women were over-represented also in this
39 sample. Moreover, the present sample consisted only of ageing employees with stable and secure
40 long-term employment and working in the capital city. Therefore the results may be generalisable,
41
42 with caution, to the Finnish municipal sector, but might not be generalisable to other age groups,
43
44 cohorts and industries.
45
46
47
48
49
50

51
52
53
54 Despite of these limitations, the present study has a number of strengths. The main strengths are the
55 use of prospective design which enabled us to examine changes in working conditions, data derived
56
57
58
59
60

1
2
3 from a well characterised occupational cohort, minor attrition, deterministic linkage to
4 administrative medication records, and an ability to examine changes in both psychosocial and
5 physical working conditions. Psychotropic medication data were based on a physician's prescription
6 and cover virtually all reimbursed psychotropic prescriptions for the analytic sample. The use of
7 register-based medication data allowed us to remove the prevalent cases and helped avoid the
8 problems related to use of self-report measures such as recall and common method bias. Extensive
9 non-response analyses were available and showed only small non-participation bias. We were able
10 to adjust for a number of important covariates such as health behaviours and obesity.
11
12
13
14
15
16
17
18
19

20 21 22 23 **CONCLUSION**

24
25
26
27
28 To conclude, this study showed that established psychosocial risk factors such as repeated exposure
29 to high job demands and low control are associated with subsequent psychotropic medication in
30 midlife and older employees. Furthermore, the results showed that also repeated and increased
31 exposure to adverse physical working conditions may contribute to subsequent psychotropic
32 medication. Identification of these potentially modifiable risk factors implies possibilities for
33 prevention.[38] Theory-based, organisationally focused interventions to tackle adverse working
34 conditions might be beneficial. Evidence for this is emerging. An intervention study in Canadian
35 hospitals showed an intervention to reduce work stress was able to produce beneficial long-term
36 effects on hospital employees' emotional well-being, in particular through reducing professional
37 burnout.[39] However, well-designed randomized controlled trials with reliable and valid objective
38 indicators of working conditions are needed to reliably test whether intentional workplace
39 interventions can prevent employee mental ill-health.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55
56
57 **Conflicts of interest:** None declared
58
59
60

Author contributions:

All authors jointly designed and conceptualised the study. Anne Kouvonen directed the implementation of the study, led all aspects of the work, performed the data analysis and drafted the article. Tea Lallukka, Eero Lahelma and Ossi Rahkonen contributed to acquisition of data. Minna Mänty, Tea Lallukka, Eero Lahelma and Ossi Rahkonen contributed to designing the study's analytic strategy, interpreting findings, reviewing the article and revising it critically for important intellectual content. All authors approved the manuscript's submission for publication.

Data sharing statement: No additional data available.

REFERENCES

- 1 OECD. Sick on the Job? Myths and Realities about Mental Health and Work. 2011.
doi:10.1787/9789264124523-en
- 2 LaMontagne AD, Martin A, Page KM, *et al.* Workplace mental health: developing an
integrated intervention approach. *BMC Psychiatry* 2014;**14**:131. doi:10.1186/1471-244X-14-
131
- 3 Stansfeld S, Candy B. Psychosocial work environment and mental health—a meta-analytic
review. *Scand J Work Environ Health* 2006;**32**:443–62. doi:10.5271/sjweh.1050
- 4 Nieuwenhuijsen K, Bruinvels D, Frings-Dresen M. Psychosocial work environment and
stress-related disorders, a systematic review. *Occup Med (Lond)* 2010;**60**:277–86.
doi:10.1093/occmed/kqq081
- 5 Smith PM, Bielecky A. The impact of changes in job strain and its components on the risk of
depression. *Am J Public Health* 2012;**102**:352–8. doi:10.2105/AJPH.2011.300376
- 6 Kolstad HA, Hansen ÅM, Kærgaard A, *et al.* Job strain and the risk of depression: Is
reporting biased? *Am J Epidemiol* 2011;**173**:94–102. doi:10.1093/aje/kwq318
- 7 Magnusson Hanson LL, Madsen IEH, Westerlund H, *et al.* Antidepressant use and
associations with psychosocial work characteristics. A comparative study of Swedish and
Danish gainfully employed. *J Affect Disord* 2013;**149**:38–45. doi:10.1016/j.jad.2012.08.023
- 8 Thielen K, Nygaard E, Rugulies R, *et al.* Job stress and the use of antidepressant medicine: a
3.5-year follow-up study among Danish employees. *Occup Environ Med* 2011;**68**:205–10.
doi:10.1136/oem.2010.057943
- 9 Virtanen M, Honkonen T, Kivimäki M, *et al.* Work stress, mental health and antidepressant

- 1
2
3 medication findings from the Health 2000 Study. *J Affect Disord* 2007;**98**:189–97.
4
5 doi:10.1016/j.jad.2006.05.034
6
7
8 10 D’Errico A, Cardano M, Landriscina T, *et al.* Workplace stress and prescription of
9
10 antidepressant medications: A prospective study on a sample of Italian workers. *Int Arch*
11
12 *Occup Environ Health* 2011;**84**:413–24. doi:10.1007/s00420-010-0586-3
13
14
15 11 Bonde JPE, Munch-Hansen T, Wieclaw J, *et al.* Psychosocial work environment and
16
17 antidepressant medication: a prospective cohort study. *BMC Public Health* 2009;**9**:262.
18
19 doi:10.1186/1471-2458-9-262
20
21
22 12 Lavigne E, Bourbonnais R. Psychosocial work environment, interpersonal violence at work
23
24 and psychotropic drug use among correctional officers. *Int J Law Psychiatry* 2010;**33**:122–9.
25
26 doi:10.1016/j.ijlp.2009.12.005
27
28
29 13 Stansfeld SA, Fuhrer R, Shipley MJ, *et al.* Work characteristics predict psychiatric disorder:
30
31 prospective results from the Whitehall II Study. *Occup Environ Med* 1999;**56**:302–7.
32
33 doi:10.1136/oem.56.5.302
34
35
36 14 Kouvonen A, Mänty M, Lallukka T, *et al.* Changes in psychosocial and physical working
37
38 conditions and common mental disorders. *Eur J Public Health* 2016;:ckw019.
39
40 doi:10.1093/eurpub/ckw019
41
42
43 15 Bentley RJ, Kavanagh A, Krnjacki L, *et al.* A longitudinal analysis of changes in job control
44
45 and mental health. *Am J Epidemiol* 2015;**182**:328–34. doi:10.1093/aje/kwv046
46
47
48 16 Strazdins L, D’Souza RM, Clements M, *et al.* Could better jobs improve mental health? A
49
50 prospective study of change in work conditions and mental health in mid-aged adults. *J*
51
52 *Epidemiol Community Health* 2011;**65**:529–34. doi:10.1136/jech.2009.093732
53
54
55 17 Laaksonen M, Lallukka T, Lahelma E, *et al.* Working conditions and psychotropic
56
57
58
59
60

- 1
2
3 medication: a prospective cohort study. *Soc Psychiatry Psychiatr Epidemiol* 2012;**47**:663–70.
4
5 doi:10.1007/s00127-011-0372-x
6
7
8 18 Lahelma E, Laaksonen M, Lallukka T, *et al.* Working conditions as risk factors for disability
9 retirement: a longitudinal register linkage study. *BMC Public Health* 2012;**12**:309.
10
11 doi:10.1186/1471-2458-12-309
12
13
14
15 19 Neupane S, Virtanen P, Luukkaala T, *et al.* A four-year follow-up study of physical working
16 conditions and perceived mental and physical strain among food industry workers. *Appl*
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 20 Woo J-M, Postolache TT. The impact of work environment on mood disorders and suicide: Evidence and implications. *Int. J. Disabil. Hum. Dev.* 2008;**7**:185–200.
- 21 Melamed S, Luz J, Green MS. Noise exposure, noise annoyance and their relation to psychological distress, accident and sickness absence among blue-collar workers--the Cordis Study. *Isr J Med Sci* 1992;**28**:629–35.
- 22 Lahelma E, Aittomäki A, Laaksonen M, *et al.* Cohort profile: The Helsinki Health Study. *Int J Epidemiol* 2013;**42**:722–30. doi:10.1093/ije/dys039
- 23 Laaksonen M, Aittomäki A, Lallukka T, *et al.* Register-based study among employees showed small nonparticipation bias in health surveys and check-ups. *J Clin Epidemiol* 2008;**61**:900–6. doi:10.1016/j.jclinepi.2007.09.010
- 24 Karasek R, Brisson C, Kawakami N, *et al.* The Job Content Questionnaire (JCQ): an instrument for internationally comparative assessments of psychosocial job characteristics. *J Occup Health Psychol* 1998;**3**:322–55. doi:10.1037/1076-8998.3.4.322
- 25 Rugulies R, Bültmann U, Aust B, *et al.* Psychosocial work environment and incidence of severe depressive symptoms: prospective findings from a 5-year follow-up of the Danish

- 1
2
3 work environment cohort study. *Am J Epidemiol* 2006;**163**:877–87. doi:10.1093/aje/kwj119
4
5
6 26 Piirainen H, Hirvonen M, Elo AL. The Work and Health interview study 2003. Basic report.
7
8 Helsinki: 2003.
9
10
11 27 Laaksonen M, Pitkaniemi J, Rahkonen O, *et al.* Work Arrangements, Physical Working
12
13 Conditions, and Psychosocial Working Conditions as Risk Factors for Sickness Absence:
14
15 Bayesian Analysis of Prospective Data. *Ann Epidemiol* 2010;**20**:332–8.
16
17 doi:10.1016/j.annepidem.2010.02.004
18
19
20 28 Saastamoinen P, Laaksonen M, Lahelma E, *et al.* Changes in working conditions and
21
22 subsequent sickness absence. *Scand J Work Environ Heal* 2014;**40**:82–8.
23
24 doi:10.5271/sjweh.3379
25
26
27 29 WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC
28
29 classification and DDD assignment 2014. Oslo: 2013.
30
31
32 30 Tsuang MT, Bar JL, Stone WS, *et al.* Gene-environment interactions in mental disorders.
33
34 *World Psychiatry* 2004;**3**:73–83.
35
36
37 31 Kivimäki M, Vahtera J, Kawachi I, *et al.* Psychosocial work environment as a risk factor for
38
39 absence with a psychiatric diagnosis: an instrumental-variables analysis. *Am J Epidemiol*
40
41 2010;**172**:167–72. doi:10.1093/aje/kwq094
42
43
44 32 DeSanto Iennaco J, Cullen MR, Cantley L, *et al.* Effects of externally rated job demand and
45
46 control on depression diagnosis claims in an industrial cohort. *Am J Epidemiol*
47
48 2010;**171**:303–11. doi:10.1093/aje/kwp359
49
50
51 33 Joensuu M, Väänänen A, Koskinen A, *et al.* Psychosocial work environment and hospital
52
53 admissions due to mental disorders: A 15-year prospective study of industrial employees. *J*
54
55 *Affect Disord* 2010;**124**:118–25. doi:10.1016/j.jad.2009.10.025
56
57
58
59
60

- 1
2
3 34 Ahola K, Honkonen T, Kivimäki M, *et al.* Contribution of burnout to the association between
4 job strain and depression: the health 2000 study. *J Occup Env Med* 2006;**48**:1023–30.
5
6
7
8 35 Stansfeld SA, Shipley MJ, Head J, *et al.* Repeated job strain and the risk of depression:
9 longitudinal analyses from the Whitehall II study. *Am J Public Health* 2012;**102**:2360–6.
10
11 doi:10.2105/AJPH.2011.300589
12
13
14
15 36 Halonen JI, Lallukka T, Pentti J, *et al.* Change in Job Strain as A Predictor of Change in
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 37 Demyttenaere, K, Bruffaerts R, Posada-Villa J, Gasquet I, *et al.* Prevalence, severity, and
unmet need for treatment of mental disorders in the World Health Organization World
Mental Health Surveys. *JAMA* 2004;**291**:2581–90.
- 38 LaMontagne a D, Krnjacki L, Kavanagh a M, *et al.* Psychosocial working conditions in a
representative sample of working Australians 2001-2008: an analysis of changes in
inequalities over time. *Occup Environ Med* 2013;**70**:639–47. doi:10.1136/oemed-2012-
101171
- 39 Bourbonnais R, Brisson C, Vézina M. Long-term effects of an intervention on psychosocial
work factors among healthcare professionals in a hospital setting. *Occup Environ Med*
2011;**68**:479–86. doi:10.1136/oem.2010.055202

Table 1. Distribution of demographics (Phase 1; 2000-2002), working conditions (Phase 1 – Phase 2; 2007) and any psychotropic medication* between Phase 2 and 2013, the Helsinki Health Study, Finland (%) (*N*=3587)

	No medication <i>N</i> (%)	Medication <i>N</i> (%)	Mean DDDs (SD)†
Sex			
Women	2034 (71)	847 (29)	496.0 (773.3)
Men	545 (77)	161 (23)	487.1 (793.0)
Age			
40	632 (72)	247 (28)	587.5 (949.9)
45	636 (68)	298 (32)	537.6 (788.6)
50	664 (72)	259 (28)	429.5 (660.0)
55	627 (76)	196 (24)	391.2 (627.2)
60	20 (71)	8 (29)	666.2 (818.6)
Job control			
High-High	1075 (73)	402 (27)	453.2 (806.6)
High-Low	358 (71)	148 (29)	458.3 (793.9)
Low-High	300 (72)	117 (28)	541.5 (761.1)
Low-Low	846 (71)	341 (29)	543.1 (749.3)
Job demands			
Low-Low	554 (74)	304 (26)	411.6 (647.4)
Low-High	419 (72)	165 (28)	476.1 (716.0)
High-Low	432 (72)	169 (28)	463.7 (694.2)
High-High	844 (70)	370 (30)	585.1 (915.3)
Physical work load			
Low-Low	1718 (73)	633 (27)	500.2 (767.4)
Low-High	248 (869)	112 (31)	455.4 (679.6)
High-Low	255 (71)	104 (29)	428.1 (704.8)
High-High	358 (69)	159 (31)	543.4 (909.2)

*Participants with psychotropic medication purchases in three months preceding Phase 2 were excluded.

† Mean of defined daily doses (DDDs) and their standard deviations (SDs) in those who had psychotropic medication purchases during follow-up.

Table 2. Age and sex adjusted hazard ratios (HRs) and their 95% confidence intervals (95% CIs) for associations of changes in working conditions between Phase 1 (2000-2002) and Phase 2 (2007) and subsequent psychotropic medication between Phase 2 and the end of 2013, the Helsinki Health Study, Finland

	Any psychotropic (N=3587)			Antidepressants (N06A) (N=3660)			Anxiolytics (N05B) (N=3867)			Sedatives and hypnotics (N05C) (N=3808)		
	N (cases)	HR	95% CI	N (cases)	HR	95% CI	N (cases)	HR	95% CI	N (cases)	HR	95% CI
Job control												
High-High	1477 (402)	1.00	Reference	1499 (264)	1.00	Reference	1573 (102)	1.00	Reference	1559 (245)	1.00	Reference
High-Low	506 (148)	1.08	0.90-1.31	518 (95)	1.04	0.82-1.32	542 (43)	1.22	0.86-1.74	532 (94)	1.13	0.89-1.43
Low-High	417 (117)	1.03	0.84-1.27	425 (80)	1.06	0.83-1.36	457 (27)	0.90	0.59-1.38	449 (91)	1.33	1.04-1.69
Low-Low	1187 (341)	1.08	0.94-1.25	1218 (244)	1.18	0.99-1.41	1295 (113)	1.37	1.05-1.79	1268 (205)	1.03	0.86-1.24
Job demands												
Low-Low	1188 (304)	1.00	Reference	1208 (205)	1.00	Reference	1267 (83)	1.00	Reference	1254 (185)	1.00	Reference
Low-High	584 (165)	1.09	0.90-1.32	598 (117)	1.10	0.88-1.38	632 (45)	1.05	0.73-1.52	619 (108)	1.20	0.94-1.52
High-Low	601 (169)	1.09	0.91-1.32	610 (106)	1.01	0.80-1.27	649 (41)	0.96	0.66-1.39	639 (110)	1.16	0.92-1.47
High-High	1214 (370)	1.22	1.04-1.42	1244 (255)	1.20	1.00-1.45	1319 (116)	1.33	1.00-1.76	1296 (232)	1.21	0.99-1.47
Physical work load												
Low-Low	2351 (633)	1.00	Reference	2390 (423)	1.00	Reference	2508 (168)	1.00	Reference	2480 (382)	1.00	Reference
Low-High	360 (112)	1.17	0.96-1.43	371 (78)	1.17	0.92-1.49	400 (26)	1.09	0.74-1.62	384 (74)	1.32	1.04-1.69
High-Low	359 (104)	1.07	0.87-1.32	369 (63)	0.93	0.71-1.21	396 (30)	0.95	0.63-1.44	398 (80)	1.25	0.96-1.60
High-High	517 (159)	1.17	0.98-1.39	530 (119)	1.30	1.06-1.59	563 (61)	1.66	1.24-2.23	546 (99)	1.22	0.98-1.52

Note: Participants with psychotropic medication purchases in question (the medication groups were not mutually exclusive) in three months preceding Phase 2 were excluded.

Table 3. Age and sex adjusted hazard ratios (HRs) and their 95% confidence intervals (95% CIs) for associations of changes in working conditions between Phase 1 (2000-2002) and Phase 2 (2007) and subsequent psychotropic medication between Phase 2 and the end of 2013, the Helsinki Health Study, Finland

	Any psychotropic (N=3587)			Antidepressants (N06A) (N=3660)			Anxiolytics (N05B) (N=3867)			Sedatives and hypnotics (N05C) (N=3808)		
	N (cases)	HR	95% CI	N (cases)	HR	95% CI	N (cases)	HR	95% CI	N (cases)	HR	95% CI
Job control												
High-High	1477 (402)	0.92	0.80-1.07	1499 (264)	0.85	0.71-1.01	1573 (102)	0.73	0.56-0.96	1559 (245)	0.97	0.81-1.17
High-Low	506 (148)	1.00	0.82-1.21	518 (95)	0.88	0.70-1.12	542 (43)	0.89	0.63-1.27	532 (94)	1.09	0.86-1.40
Low-High	417 (117)	0.95	0.77-1.18	425 (80)	0.90	0.70-1.16	457 (27)	0.66	0.43-1.00	449 (91)	1.29	1.00-1.65
Low-Low	1187 (341)	1.00	Reference	1218 (244)	1.00	Reference	1295 (113)	1.00	Reference	1268 (205)	1.00	Reference
Job demands												
Low-Low	1188 (304)	0.82	0.71-0.96	1208 (205)	0.83	0.69-1.00	1267 (83)	0.75	0.57-1.00	1254 (185)	0.83	0.68-1.01
Low-High	584 (165)	0.90	0.75-1.08	598 (117)	0.91	0.73-1.14	632 (45)	0.79	0.56-1.12	619 (108)	0.99	0.79-1.25
High-Low	601 (169)	0.90	0.75-1.08	610 (106)	0.84	0.67-1.05	649 (41)	0.72	0.50-1.03	639 (110)	0.96	0.77-1.21
High-High	1214 (370)	1.00	Reference	1244 (255)	1.00	Reference	1319 (116)	1.00	Reference	1296 (232)	1.00	Reference
Physical work load												
Low-Low	2351 (633)	0.85	0.72-1.02	2390 (423)	0.77	0.63-0.95	2508 (168)	0.60	0.45-0.81	2480 (382)	0.82	0.66-1.03
Low-High	360 (112)	0.91	0.71-1.17	371 (78)	0.90	0.68-1.20	400 (26)	0.66	0.43-1.02	384 (74)	1.09	0.81-1.46
High-Low	359 (104)	1.00	0.78-1.27	369 (63)	0.72	0.53-0.98	396 (30)	0.57	0.36-0.90	398 (80)	1.03	0.76-1.39
High-High	517 (159)	1.00	Reference	530 (119)	1.00	Reference	563 (61)	1.00	Reference	546 (99)	1.00	Reference

Note: Participants with psychotropic medication purchases in question (the medication groups were not mutually exclusive) in three months preceding Phase 2 were excluded.

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	page	Recommendation
Title and abstract	1	p1	(a) Indicate the study's design with a commonly used term in the title or the abstract
		p2	(b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction			
Background/rationale	2	p4-5	Explain the scientific background and rationale for the investigation being reported
Objectives	3	p5	State specific objectives, including any prespecified hypotheses
Methods			
Study design	4	p5-6	Present key elements of study design early in the paper
Setting	5	p5-6	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	p5-6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up
			<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls
			<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants
			(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed
			<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	p6-8	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	p6-8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	p5-6	Describe any efforts to address potential sources of bias
Study size	10	p5-6	Explain how the study size was arrived at
Quantitative variables	11	p6-8	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	p8-9	(a) Describe all statistical methods, including those used to control for confounding
		p8-9	(b) Describe any methods used to examine subgroups and interactions
		p6	(c) Explain how missing data were addressed
		p5-6	(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed
			<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed
			<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy
		NA	(e) Describe any sensitivity analyses

Continued on next page

Results			
Participants	13*	p5-6	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
		p5-6	(b) Give reasons for non-participation at each stage
		considered	(c) Consider use of a flow diagram
Descriptive data	14*	p9+Table 1	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders
		p9	(b) Indicate number of participants with missing data for each variable of interest
		p8-9	(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data	15*	Tables	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time
			<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure
			<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	p10+Tables 2-3	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
		p7-8	(b) Report category boundaries when continuous variables were categorized
			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	p9	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion			
Key results	18	p10-11	Summarise key results with reference to study objectives
Limitations	19	p12-14	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	p14	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	p13	Discuss the generalisability (external validity) of the study results
Other information			
Funding	22	p1	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Changes in psychosocial and physical working conditions and psychotropic medication in ageing public sector employees: a record-linkage follow-up study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015573.R1
Article Type:	Research
Date Submitted by the Author:	18-Apr-2017
Complete List of Authors:	Kouvonen, Anne; University of Helsinki, Social Research; SWPS University of Social Sciences and Humanities, Faculty in Wroclaw Mänty, Minna; Helsinki University, Department of Public Health Lallukka, Tea; Finnish Institute of Occupational Health, Pietilainen, Olli; University of Helsinki, Hjelt Institute, Department of Public Health Lahelma, Eero; University of Helsinki, Department of Public Health Rahkonen, Ossi; University of Helsinki, Department of Public Health
Primary Subject Heading:	Occupational and environmental medicine
Secondary Subject Heading:	Epidemiology
Keywords:	MENTAL HEALTH, longitudinal studies, work stress

SCHOLARONE™
Manuscripts

Only

1
2
3 **Changes in psychosocial and physical working conditions and**
4
5
6 **psychotropic medication in ageing public sector employees: a record-**
7
8
9 **linkage follow-up study**
10

11
12
13
14
15 Anne Kouvonen,^{1,2,3} Minna Mänty,⁴ Tea Lallukka,^{4,5} Olli Pietiläinen,⁴ Eero Lahelma,⁴ Ossi
16
17 Rahkonen⁴
18
19

20
21
22 ¹Faculty of Social Sciences, University of Helsinki, Helsinki, Finland
23

24 ²SWPS University of Social Sciences and Humanities in Wroclaw, Wroclaw, Poland
25

26 ³Administrative Data Research Centre (Northern Ireland), Centre for Public Health, Queen's
27
28 University Belfast, Belfast, UK
29

30 ⁴Department of Public Health, University of Helsinki, Helsinki, Finland
31

32 ⁵Finnish Institute of Occupational Health, Helsinki, Finland
33
34
35
36

37 *Address for correspondence: Dr Anne Kouvonen, Department of Social Research, P.O. Box 54,
38
39 00014 University of Helsinki, Finland.
40

41
42 Telephone: +358 50 4487113; Email: anne.kouvonen@helsinki.fi
43
44

45 Manuscript statistics: 240 words in Abstract, 3223 words in text, 41 references, 3 Tables, 3 Figures
46
47

48 **Funding**

49

50
51 This work was supported by the Finnish Work Environment Fund (grant 112231), the Academy of
52
53 Finland (grants 1129225, 1257362, 1294514) and the University of Helsinki. AK was supported by
54
55 the Economic and Social Research Council (ESRC) (grant ES/L007509/1). MM was supported by
56
57
58
59
60

1
2
3 the Finnish Work Environment Fund (grant 115182) and the Juho Vainio Foundation. TL was
4
5 supported by the Academy of Finland (grant 287488).
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Abstract

Objectives: To investigate whether changes in psychosocial and physical working conditions are associated with subsequent psychotropic medication in ageing employees.

Methods: Data were from the Helsinki Health Study, a cohort study of Finnish municipal employees, aged 40-60 years at Phase 1 (2000-2002). Changes in psychosocial and physical working conditions were measured between Phase 1 and Phase 2 (2007). Survey data were longitudinally linked to data on prescribed, reimbursed psychotropic medication purchases (ATC) obtained from the registers of the Social Insurance Institution of Finland between the Phase 2 survey and December 2013 (N=3587; 80% women). Outcomes were any psychotropic medication; antidepressants (N06A); anxiolytics (N05B); and sedatives and hypnotics (N05C). Cox regression analyses were performed.

Results: During the follow-up 28% of the participants were prescribed psychotropic medication. Repeated exposures to low job control, high job demands and high physical work load were associated with an increased risk of subsequent antidepressant and anxiolytic medication. Increased and repeated exposure to high physical work load, increased job control and repeated high job demands were associated with subsequent sedative and hypnotic medication. Age and sex adjusted hazard ratios varied from 1.18 to 1.66. Improvement in job control was associated with a lower risk of anxiolytic, but with a higher risk of sedatives and hypnotic medication. Decreased physical work load was associated with a lower risk of antidepressant and anxiolytic medication.

Conclusion: Improvement in working conditions could lower the risk of mental ill-health indicated by psychotropic medication.

Keywords: mental health; longitudinal studies; work stress

1
2
3 **Abbreviations:** ATC, Anatomical Therapeutic Chemical; BMI, body mass index; CI, confidence
4 interval; DDD, defined daily dose; HR, hazard ratio; WHO, World Health Organization
5
6
7
8
9

10 **Strengths and limitations of this study**

- 13 • Unlike previous studies, we were able to examine changes in both psychosocial and physical
14 working conditions.
- 15 • Data were derived from a well characterised occupational cohort which was
16 deterministically linked to administrative medication records.
- 17 • The use of register-based medication data allowed us to remove the prevalent cases and
18 helped avoid the problems related to use of self-report measures such as recall and common
19 method bias.
- 20 • Due to relatively long interval between the two working conditions measurements, the study
21 could have underestimated the effect of changing working conditions on subsequent
22 psychotropic medication.
- 23 • We did not have information about the clinical indication the examined medication was
24 prescribed for.
- 25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Mental ill-health is a growing concern in working populations.[1] Adverse working conditions have been proposed as potentially modifiable risk factors for mental ill-health.[2] Indeed, there is evidence that exposure to adverse psychosocial working conditions including low job control and high job demands, are associated with an increased risk of mental ill-health.[3–7] However, the majority of earlier studies have measured both exposure and outcome using self-reports, which can lead to inflated associations and common method bias.[8] Other studies have avoided these problems by using register-based outcomes such as psychotropic medication, which is a commonly used marker of mental ill-health in a population.[9–14]

Most of the earlier studies have assessed exposure to adverse working conditions only at one time point, and there is a paucity of large-scale studies examining the association between changes in psychosocial working conditions and mental ill-health. Of a few studies that have separately assessed the effects of changes in job control and job demands on mental ill-health, three found that adverse changes in job demands had a stronger effect on the risk of self-reported mental ill-health than adverse changes in job control, whereas positive changes in these domains did not result in improvement in mental health.[5,15,16] In a recent study within-person increase in job control was associated with better self-reported mental health;[17] and in another study both improvements and deterioration in job demands and job control predicted change in mental health.[18] However, studies assessing the association between changes in job control and job demands and a more objective measure of mental ill-health, such as recorded psychotropic medication, are lacking.

Moreover, psychosocial working conditions have dominated discussion about the work-related determinants of poor mental health, even though there is evidence that also physical working

1
2
3 conditions are associated with mental ill-health. In the present cohort, increased and repeated
4 exposure to repetitive movements and repeated exposure to awkward postures and rotation of back
5 was associated with an increased likelihood of common mental disorders,[16] desktop work was
6 associated with purchases of sleeping pills among women,[19] and computer work was a risk factor
7 for disability retirement due to mental causes.[20] In another study deteriorating physical working
8 conditions increased perceived mental strain.[21] A review of the impact of working environment
9 on mood disorders discussed the potential mechanisms; however actual studies conducted in
10 employee cohorts were rare.[22] In a study among blue-collar workers exposure to noise intensified
11 anxiety and depression in women.[23]

12
13
14 We set out this study to examine the associations between changes in psychosocial and physical
15 working conditions and subsequent psychotropic medication.

16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

METHODS

Data

The data came from the Helsinki Health Study, which is a cohort study designed to investigate social and work-related determinants of health and well-being.[24] The target population is the staff of the City of Helsinki, Finland. Phase 1 questionnaire surveys were collected in 2000, 2001 and 2002 among employees turning 40, 45, 50, 55 or 60 each year (N=8960, response rate 67%; 80% of participants women). Phase 2 survey data were collected in 2007 (N=7332, response rate 83%).

Earlier non-response analysis showed that the participants broadly represent the target population.[24] Survey data were linked to national records using a unique personal identification number for those respondents who had given written consent for the linkage (74%; N=6498).

1
2
3 Consenting for the data linkage followed a similar pattern as the non-response, except that men
4
5 provided consent slightly more often than women.[24,25]
6
7
8

9
10 In the present study, of those who consented to linkage, only participants who were still employed
11
12 at Phase 2 were included (N=4207). Men, manual workers and those who reported common mental
13
14 disorders at Phase 1 had slightly more often left the employment between the two phases (all *p*
15
16 values < 0.01, data not shown). Because of the age structure of the cohort, the majority (86%) of
17
18 those who replied at Phase 2 and stated that they were not employed, had retired.
19
20

21
22 In addition, we excluded those with purchases of psychotropic medication in three months
23
24 preceding Phase 2 (n=337 for any psychotropic medication). Finally, we excluded those participants
25
26 who had missing values for any of the study variables (n=283). The exclusions resulted in a final
27
28 analytic sample of 3587 participants for the analyses examining any psychotropic medication.
29
30
31

32 33 34 **Ethics**

35
36
37
38 The Helsinki Health Study protocol was approved by the Ethics Committees of the Department of
39
40 Public Health, University of Helsinki, and the health authorities of the City of Helsinki. The study
41
42 conformed to the principles embodied in the Declaration of Helsinki.
43
44
45

46 47 48 **Measurements**

49 50 51 52 53 **Working conditions**

54
55
56
57
58
59
60

1
2
3 We used a version of Karasek's Job Content Questionnaire[26] to measure job control and job
4 demands. Job control was assessed by nine and job demands by five items. Missing values were
5 replaced by item modes for those having responded to at least eight job control and four job
6 demands items, respectively. Job control and job demands were both dichotomised at the
7 median.[9,27]
8
9

10
11
12
13
14
15
16 *Physical work load* was assessed with an 18-item instrument developed at the Finnish Institute of
17 Occupational Health.[28] Missing values were replaced by item modes for those having responded
18 to at least fourteen items. Factor analysis showed that the questions loaded on three factors, of
19 which the first one was interpreted to best measure physical work load. The items with the largest
20 positive standardised scoring coefficients were: awkward working positions; rotation of the back;
21 repetitive movements; and heavy physical effort or lifting and carrying heavy loads. Physical work
22 load factor score was dichotomised at the highest quartile.[29]
23
24
25
26
27
28
29
30
31
32
33

34 Changes in psychosocial and physical working conditions were measured by a four-category
35 variable for each of the three exposure variables: (i) repeated low exposure (low exposure at Phase
36 1 and low exposure at Phase 2); (ii) increased exposure (low exposure at Phase 1 and high exposure
37 at Phase 2); (iii) decreased exposure (high exposure at Phase 1 and low exposure at Phase 2); (iv)
38 repeated high exposure (high exposure at Phase 1 and high exposure at Phase 2).[30]
39
40
41
42
43
44
45
46
47

48 **Psychotropic medication**

49
50

51
52 Data on psychotropic medication were derived from the Finnish Prescription Register. This register
53 is maintained by the Social Insurance Institution and it includes records of all prescribed
54 psychotropic medication purchases reimbursed to Finnish residents in non-institutional settings. For
55
56
57
58
59
60

1
2
3 each dispensed drug, the record includes the dispensing date, the WHO Anatomical Therapeutic
4 Chemical (ATC) code, and the quantity prescribed and purchased as the number of defined daily
5 doses (DDDs).[31] We extracted information on all purchases of antidepressants, anxiolytics,
6
7 sedatives and hypnotics (ATC-codes N06A, N05B and N05C, respectively; see Appendix 1) in our
8
9 analytic sample, following Phase 2 survey date (index date) during the follow-up until December
10
11 31, 2013. Dates of deaths were retrieved from Statistics Finland (the Causes of Death Register).
12
13
14
15
16
17

18 **Covariates**

19
20
21 All covariates were survey-based and from Phase 1. We measured age, sex and marital status
22
23 (married/cohabiting vs. other). Moreover, we measured current smoking (yes vs. no), binge
24
25 drinking (six or more units of alcohol on one occasion once a month or more often), low physical
26
27 activity (less than 14 metabolic equivalent hours per week) and body mass index, which was
28
29 categorised as non-obese ($\leq 30 \text{ kg/m}^2$) and obese ($>30 \text{ kg/m}^2$).
30
31
32
33
34
35

36 **Statistical analysis**

37
38
39 The associations between sex, age and psychotropic medication during the follow-up were first
40
41 analysed using the Chi-square test. Cox proportional hazard models were fitted to examine the
42
43 association between change in psychosocial and physical working conditions between Phase 1 and
44
45 Phase 2 and subsequent psychotropic medication during the follow-up. We estimated hazard ratios
46
47 (HRs) and their 95% confidence intervals (95% CIs) for psychotropic medication by changes in
48
49 each working condition by first controlling for age and sex; then further controlling for marital
50
51 status, smoking, binge drinking, low physical activity, and obesity. In the first analysis, for each
52
53 working condition, the reference group was the most favourable working condition (i.e. repeated
54
55 high control, repeated low demands, and repeated high physical work load, respectively). To
56
57
58
59
60

1
2
3 examine the effects of positive changes in working conditions, we conducted an additional analysis
4 using the least favourable working condition as the reference group. The follow-up began from the
5 date of the Phase 2 survey response and ended at the first record of the psychotropic medication
6 purchase, death, or on 31 December, 2013, whichever came first.
7
8
9

10
11
12 We conducted the Therneau-Grambsch nonproportional hazards test, complementing it with the
13 smoothed scatter plot of Schoenfeld residuals against explanatory variables. The visual inspection
14 of the scatter plots supports the interpretation that the proportional hazards assumption was met.
15 The scatter plots for any psychotropic medication are presented in Appendix 2. Moreover, the
16 interaction terms between each working condition and logarithm of the follow-up period for any
17 psychotropic medication as well as for each medication group were non-significant (all $p > 0.05$),
18 further confirming that the proportional-hazards assumption was justified
19
20
21
22
23
24
25
26
27
28

29 None of the gender interactions were statistically significant (all interaction terms sex*working
30 condition $p > 0.05$); we therefore analysed women and men together, adjusting for gender.
31
32
33
34
35

36 The analyses were conducted with SAS 9.4 (SAS Institute, Inc., Cary, North Carolina) and R.
37
38
39
40
41

42 RESULTS

43
44
45
46

47 **Table 1** shows the distribution of the key study variables by any prescribed psychotropic
48 medication during follow-up. The mean age at baseline was 47.5 years. A total of 1008 participants
49 (28%) recorded at least one purchase of prescribed psychotropic medication during the mean
50 follow-up of 5.0 years. Psychotropic medication was more prevalent among women (29%) than
51 among men (23%). Nineteen percent of the participants received antidepressant medication during
52
53
54
55
56
57
58
59
60

1
2
3 the follow-up. The corresponding figures for anxiolytics and for hypnotics/sedatives were 7% and
4
5 17%, respectively.
6
7

8
9
10 As displayed in **Table 2**, after adjustment for age and sex, repeated high job demands (HR=1.22,
11
12 95% CI: 1.04-1.42) were associated with any psychotropic medication. The association between
13
14 repeated high physical work load and any psychotropic medication was marginally statistically
15
16 significant (HR=1.17, 95% CI: 0.98-1.39). Figures 1, 2 and 3 show survival curves for any
17
18 psychotropic medication by changes in working conditions.
19

20
21
22 When the groups of psychotropic medication were examined separately, repeated high job demands
23
24 (HR=1.20, 95% CI: 1.00-1.45) and repeated high physical work load (HR=1.30, 95% CI: 1.06-1.59)
25
26 were associated with subsequent antidepressant medication, whereas repeated low job control (1.37,
27
28 95% CI: 1.05-1.79), repeated high demands (HR=1.33, 95% CI: 1.00-1.76), and repeated high
29
30 physical work load (HR=1.66, 95% CI: 1.24-2.23) were associated with subsequent anxiolytic
31
32 medication. Increased job control and increased physical work load were associated with
33
34 subsequent sedative and hypnotic medication. Repeated high demands and repeated physical work
35
36 load showed associations with subsequent sedative and hypnotic medication. Further adjustment for
37
38 marital status, health behaviours, and obesity only marginally changed the HRs (data not shown).
39

40
41
42 We additionally tested whether favourable change in working conditions was associated with a
43
44 lower risk of psychotropic medication, by using the least favourable working conditions as
45
46 reference categories (Table 3). Compared to repeatedly low job control, increased job control was
47
48 associated with a lower risk of anxiolytic, but a higher risk of sedative and hypnotic medication.
49
50 Compared to repeatedly high physical work load, decreased physical load was associated with a
51
52 lower risk of subsequent antidepressant and anxiolytic medication.
53
54
55
56
57
58
59
60

DISCUSSION

In this study, repeated and increased exposure to adverse psychosocial and physical working conditions was associated with subsequent psychotropic medication. It is notable that we found similar associations for both types of working conditions. However, the associations between adverse working conditions and subsequent psychotropic medication were modest. This is expected: the aetiology of mental disorders – the main indication for psychotropic medication - is complex and multifactorial, involving multiple social, psychological and biological factors.[32] Exposure to adverse working conditions or a positive or negative change in them is only one such factor.

Compared to employees with repeated low job demands, the employees whose job demands had increased had a higher risk of purchasing any psychotropic medication as well as antidepressant medication. Antidepressant medication is likely to reflect depression and other mental disorders. A number of previous studies have shown a link between high job demands and an increased risk of mental ill-health.[3,15,16,33]

Previous results for job control have been mixed. In a meta-analytic review published in 2006 low decision latitude predicted common mental disorders.[3] In terms of more objective outcomes, null results have been reported for psychotropic prescriptions,[13,34] whereas one previous study showed an association between high decision authority and an elevated risk of hospital admissions due to mental disorders.[35] In our study increased job control was associated with a subsequent sedative and hypnotic medication. In a previous study, active jobs, that is, those with high levels of control and demands, were associated with a higher risk of depression and burnout.[36] It is possible that increased decision authority and high responsibility may become a burden for some employees. It is also possible that high job control reflects not only working conditions but also

1
2
3 characteristics of a generally more active employee with a higher likelihood of seeking
4
5 treatment.[35]
6
7

8
9
10 The result that increased job control was associated with a lower risk of anxiolytic, but a higher risk
11
12 of sedative and hypnotic medication seems conflicting and is difficult to explain. This result may
13
14 reflect the fact that some anxiolytics (e.g. lorazepam, diazepam) can be used as hypnotics as well,
15
16 and a switch between some anxiolytic benzodiazepine and hypnotic benzodiazepine could confound
17
18 these associations. Unfortunately we had no information about the indication of the medication use.
19
20

21
22
23 When comparing to the least favourable working conditions, increased job control was associated
24
25 with a lower risk of anxiolytic medication; and decreased physical load was associated with a lower
26
27 risk of antidepressant and anxiolytic medication. Two earlier studies did not find an association
28
29 between favourable changes in psychosocial working conditions and a decreased risk of subsequent
30
31 mental ill-health.[15,37] However, in one previous study both improvements and deterioration in
32
33 job demands and control were associated with corresponding improvements or deterioration in
34
35 mental health,[18] and in another study decrease of job strain was associated with a lower
36
37 likelihood of repeated insomnia symptoms.[38]
38
39
40
41
42

43 Most of the earlier studies have investigated only psychosocial working conditions. In the present
44
45 study repeatedly high and increased physical work load were associated with subsequent
46
47 psychotropic medication. In fact, the strongest association (HR=1.66 for anxiolytic medication)
48
49 between working conditions and psychotropic medication was found for repeated high physical
50
51 workload. Our findings thus support the earlier findings in the present and other cohorts, which
52
53 have shown associations between exposure to adverse physical working conditions and common
54
55
56
57
58
59
60

1
2
3 mental disorders,[16] disability retirement due to mental disorders,[20] purchases of sleeping
4
5 pills,[19] and perceived mental strain.[21]
6
7

8 9 **Methodological considerations**

10
11
12
13
14 Certain limitations need to be acknowledged. First, because of the relatively long interval between
15
16 the two working conditions measurements, this study could have underestimated the effect of
17
18 changing working conditions on subsequent medication. Moreover, working conditions could have
19
20 changed several times during the follow-up; this could have resulted in more conservative effect
21
22 sizes.
23

24
25
26 Second, we were unable to assess the magnitude of change in working conditions; the use of these
27
28 crude measures only assessed whether a participant had moved from one category to another.
29
30 Furthermore, we did not have information about the prior duration of exposure to adverse working
31
32 conditions. The use of thresholds may have led to underestimates of true effects of changing
33
34 working conditions.[5]
35

36
37
38
39 Third, we did not have information about clinical indication the examined medication was
40
41 prescribed for. Even if psychotropic medication is a recommended treatment for a number of mental
42
43 disorders and prescription data derived from official registers can therefore be considered as a proxy
44
45 for mental disorders requiring treatment, these medications are prescribed also for other conditions.
46
47 On the other hand, it has been shown that mental disorders are underdiagnosed and
48
49 undertreated.[39]
50
51

52
53
54
55 Fourth, we did not have information about the discontinuation of psychotropic medication. Even if
56
57 the participants had purchased the prescribed medication from the pharmacy, they could have
58
59
60

1
2
3 discontinued the use. Discontinuation of psychotropic drugs can lead to different meanings: the
4
5 discontinuation of antidepressants can be associated with either side effects or lack of follow-up
6
7 controls, whereas sporadic use of anxiolytics and hypnotics can be due to temporary discomfort.
8
9

10
11 Fifth, participants who left employment between Phase 1 and Phase 2 were not included in the
12
13 study. It has been suggested that the age-related health selection may result in a more resilient older
14
15 worker population [37]. A healthy worker effect may thus have led to underestimation of the
16
17 associations.
18
19

20
21
22 Finally, even if the data consisted of a broad range of both manual and non-manual occupations, the
23
24 study population was not a representative sample of the total working population. Because the
25
26 Finnish public sector workforce is female-dominated, women were over-represented also in this
27
28 sample. Moreover, the present sample consisted only of ageing employees with stable and secure
29
30 long-term employment and working in the capital city. Therefore the results may be generalisable,
31
32 with caution, to the Finnish municipal sector, but might not be generalisable to other age groups,
33
34 cohorts and industries.
35
36
37

38
39
40 Despite of these limitations, the present study has a number of strengths. The main strengths are the
41
42 use of prospective design which enabled us to examine changes in working conditions, data derived
43
44 from a well characterised occupational cohort, minor attrition, deterministic linkage to
45
46 administrative medication records, and an ability to examine changes in both psychosocial and
47
48 physical working conditions. Psychotropic medication data were based on a physician's prescription
49
50 and cover virtually all reimbursed psychotropic prescriptions for the analytic sample. The use of
51
52 register-based medication data allowed us to remove the prevalent cases and helped avoid the
53
54 problems related to use of self-report measures such as recall and common method bias. Extensive
55
56
57
58
59
60

1
2
3 non-response analyses were available and showed only small non-participation bias. We were able
4
5 to adjust for a number of important covariates such as health behaviours and obesity.
6
7

8 9 **CONCLUSION**

10
11
12
13
14 To conclude, this study showed that established psychosocial risk factors such as repeated exposure
15
16 to high job demands and low control are associated with subsequent psychotropic medication in
17
18 midlife and older employees. Furthermore, the results showed that also repeated and increased
19
20 exposure to adverse physical working conditions may contribute to subsequent psychotropic
21
22 medication. Identification of these potentially modifiable risk factors implies possibilities for
23
24 prevention.[40] Theory-based, organisationally focused interventions to tackle adverse working
25
26 conditions might be beneficial. Evidence for this is emerging. An intervention study in Canadian
27
28 hospitals showed an intervention to reduce work stress was able to produce beneficial long-term
29
30 effects on hospital employees' emotional well-being, in particular through reducing professional
31
32 burnout.[41] However, well-designed randomized controlled trials with reliable and valid objective
33
34 indicators of working conditions are needed to reliably test whether intentional workplace
35
36 interventions can prevent employee mental ill-health.
37
38
39
40
41
42

43 **Conflicts of interest:** None declared
44
45

46 **Author contributions:**

47
48 All authors jointly designed and conceptualised the study. Anne Kouvonen directed the
49
50 implementation of the study, led all aspects of the work, and drafted the article. Anne Kouvonen
51
52 and Olli Pietiläinen performed the data analysis. Tea Lallukka, Eero Lahelma, Olli Pietiläinen and
53
54 Ossi Rahkonen contributed to acquisition of data. Minna Mänty, Tea Lallukka, Olli Pietiläinen,
55
56
57
58
59
60

1
2
3 Eero Lahelma and Ossi Rahkonen contributed to designing the study's analytic strategy,
4 interpreting findings, reviewing the article and revising it critically for important intellectual
5 content. All authors approved the manuscript's submission for publication.
6
7
8
9

10 **Data sharing statement:** No additional data available.
11

12 **Figure legends**

13
14
15
16
17 Figure 1. Survival curves for any psychotropic medication by changes in job control

18 Figure 2. Survival curves for any psychotropic medication by changes in job demands

19
20
21 Figure 3. Survival curves for any psychotropic medication by changes in physical working
22 conditions
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

- 1 OECD. Sick on the Job? Myths and Realities about Mental Health and Work. 2011.
doi:10.1787/9789264124523-en
- 2 LaMontagne AD, Martin A, Page KM, *et al*. Workplace mental health: developing an
integrated intervention approach. *BMC Psychiatry* 2014;**14**:131. doi:10.1186/1471-244X-14-
131
- 3 Stansfeld S, Candy B. Psychosocial work environment and mental health—a meta-analytic
review. *Scand J Work Environ Health* 2006;**32**:443–62. doi:10.5271/sjweh.1050
- 4 Nieuwenhuijsen K, Bruinvels D, Frings-Dresen M. Psychosocial work environment and
stress-related disorders, a systematic review. *Occup Med (Lond)* 2010;**60**:277–86.
doi:10.1093/occmed/kqq081
- 5 Smith PM, Bielecky A. The impact of changes in job strain and its components on the risk of
depression. *Am J Public Health* 2012;**102**:352–8. doi:10.2105/AJPH.2011.300376
- 6 Traweger C, Kinzl JF, Traweger-Ravanelli B, *et al*. Psychosocial factors at the workplace--
do they affect substance use? Evidence from the Tyrolean workplace study.
Pharmacoepidemiol Saf 2004;**13**:399–403. doi:10.1002/pds.955
- 7 Ngoundo-Mbongue TB, Niezborala M, Sulem P, *et al*. Psychoactive drug consumption:
Performance-enhancing behaviour and pharmacodependence in workers.
Pharmacoepidemiol Drug Saf 2005;**14**:81–9. doi:10.1002/pds.1006
- 8 Kolstad HA, Hansen ÅM, Kærgaard A, *et al*. Job strain and the risk of depression: Is
reporting biased? *Am J Epidemiol* 2011;**173**:94–102. doi:10.1093/aje/kwq318
- 9 Magnusson Hanson LL, Madsen IEH, Westerlund H, *et al*. Antidepressant use and

- 1
2
3 associations with psychosocial work characteristics. A comparative study of Swedish and
4
5 Danish gainfully employed. *J Affect Disord* 2013;**149**:38–45. doi:10.1016/j.jad.2012.08.023
6
7
8
9
10 Thielen K, Nygaard E, Rugulies R, *et al.* Job stress and the use of antidepressant medicine: a
11
12 3.5-year follow-up study among Danish employees. *Occup Environ Med* 2011;**68**:205–10.
13
14 doi:10.1136/oem.2010.057943
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 11 Virtanen M, Honkonen T, Kivimäki M, *et al.* Work stress, mental health and antidepressant
medication findings from the Health 2000 Study. *J Affect Disord* 2007;**98**:189–97.
doi:10.1016/j.jad.2006.05.034
- 12 D'Errico A, Cardano M, Landriscina T, *et al.* Workplace stress and prescription of
antidepressant medications: A prospective study on a sample of Italian workers. *Int Arch
Occup Environ Health* 2011;**84**:413–24. doi:10.1007/s00420-010-0586-3
- 13 Bonde JPE, Munch-Hansen T, Wieclaw J, *et al.* Psychosocial work environment and
antidepressant medication: a prospective cohort study. *BMC Public Health* 2009;**9**:262.
doi:10.1186/1471-2458-9-262
- 14 Lavigne E, Bourbonnais R. Psychosocial work environment, interpersonal violence at work
and psychotropic drug use among correctional officers. *Int J Law Psychiatry* 2010;**33**:122–9.
doi:10.1016/j.ijlp.2009.12.005
- 15 Stansfeld SA, Fuhrer R, Shipley MJ, *et al.* Work characteristics predict psychiatric disorder:
prospective results from the Whitehall II Study. *Occup Environ Med* 1999;**56**:302–7.
doi:10.1136/oem.56.5.302
- 16 Kouvonen A, Mänty M, Lallukka T, *et al.* Changes in psychosocial and physical working
conditions and common mental disorders. *Eur J Public Health* 2016;:ckw019.
doi:10.1093/eurpub/ckw019

- 1
2
3 17 Bentley RJ, Kavanagh A, Krnjacki L, *et al.* A longitudinal analysis of changes in job control
4 and mental health. *Am J Epidemiol* 2015;**182**:328–34. doi:10.1093/aje/kwv046
5
6
7
8 18 Strazdins L, D’Souza RM, Clements M, *et al.* Could better jobs improve mental health? A
9 prospective study of change in work conditions and mental health in mid-aged adults. *J*
10
11
12
13
14
15 19 Laaksonen M, Lallukka T, Lahelma E, *et al.* Working conditions and psychotropic
16 medication: a prospective cohort study. *Soc Psychiatry Psychiatr Epidemiol* 2012;**47**:663–70.
17
18
19
20
21
22
23 20 Lahelma E, Laaksonen M, Lallukka T, *et al.* Working conditions as risk factors for disability
24 retirement: a longitudinal register linkage study. *BMC Public Health* 2012;**12**:309.
25
26
27
28
29
30 21 Neupane S, Virtanen P, Luukkaala T, *et al.* A four-year follow-up study of physical working
31 conditions and perceived mental and physical strain among food industry workers. *Appl*
32
33
34
35
36
37 22 Woo J-M, Postolache TT. The impact of work environment on mood disorders and suicide:
38 Evidence and implications. *Int. J. Disabil. Hum. Dev.* 2008;**7**:185–200.
39
40
41
42 23 Melamed S, Luz J, Green MS. Noise exposure, noise annoyance and their relation to
43 psychological distress, accident and sickness absence among blue-collar workers--the Cordis
44
45
46
47
48
49 24 Lahelma E, Aittomäki A, Laaksonen M, *et al.* Cohort profile: The Helsinki Health Study. *Int*
50
51
52
53
54
55 25 Laaksonen M, Aittomäki A, Lallukka T, *et al.* Register-based study among employees
56 showed small nonparticipation bias in health surveys and check-ups. *J Clin Epidemiol*
57
58
59
60

- 2008;**61**:900–6. doi:10.1016/j.jclinepi.2007.09.010
- 26 Karasek R, Brisson C, Kawakami N, *et al.* The Job Content Questionnaire (JCQ): an instrument for internationally comparative assessments of psychosocial job characteristics. *J Occup Health Psychol* 1998;**3**:322–55. doi:10.1037/1076-8998.3.4.322
- 27 Rugulies R, Bültmann U, Aust B, *et al.* Psychosocial work environment and incidence of severe depressive symptoms: prospective findings from a 5-year follow-up of the Danish work environment cohort study. *Am J Epidemiol* 2006;**163**:877–87. doi:10.1093/aje/kwj119
- 28 Piirainen H, Hirvonen M, Elo AL. The Work and Health interview study 2003. Basic report. Helsinki: 2003.
- 29 Laaksonen M, Pitkäniemi J, Rahkonen O, *et al.* Work Arrangements, Physical Working Conditions, and Psychosocial Working Conditions as Risk Factors for Sickness Absence: Bayesian Analysis of Prospective Data. *Ann Epidemiol* 2010;**20**:332–8. doi:10.1016/j.annepidem.2010.02.004
- 30 Saastamoinen P, Laaksonen M, Lahelma E, *et al.* Changes in working conditions and subsequent sickness absence. *Scand J Work Environ Heal* 2014;**40**:82–8. doi:10.5271/sjweh.3379
- 31 WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2014. Oslo: 2013.
- 32 Tsuang MT, Bar JL, Stone WS, *et al.* Gene-environment interactions in mental disorders. *World Psychiatry* 2004;**3**:73–83.
- 33 Kivimäki M, Vahtera J, Kawachi I, *et al.* Psychosocial work environment as a risk factor for absence with a psychiatric diagnosis: an instrumental-variables analysis. *Am J Epidemiol* 2010;**172**:167–72. doi:10.1093/aje/kwq094

- 1
2
3 34 DeSanto Iennaco J, Cullen MR, Cantley L, *et al.* Effects of externally rated job demand and
4 control on depression diagnosis claims in an industrial cohort. *Am J Epidemiol*
5 2010;**171**:303–11. doi:10.1093/aje/kwp359
6
7
8
9
10 35 Joensuu M, Väänänen A, Koskinen A, *et al.* Psychosocial work environment and hospital
11 admissions due to mental disorders: A 15-year prospective study of industrial employees. *J*
12 *Affect Disord* 2010;**124**:118–25. doi:10.1016/j.jad.2009.10.025
13
14
15
16
17 36 Ahola K, Honkonen T, Kivimäki M, *et al.* Contribution of burnout to the association between
18 job strain and depression: the health 2000 study. *J Occup Env Med* 2006;**48**:1023–30.
19
20
21
22 37 Stansfeld SA, Shipley MJ, Head J, *et al.* Repeated job strain and the risk of depression:
23 longitudinal analyses from the Whitehall II study. *Am J Public Health* 2012;**102**:2360–6.
24 doi:10.2105/AJPH.2011.300589
25
26
27
28
29 38 Halonen JI, Lallukka T, Pentti J, *et al.* Change in Job Strain as A Predictor of Change in
30 Insomnia Symptoms: Analyzing Observational Data as A Non-randomized Pseudo-Trial.
31 *Sleep* 2016.
32
33
34
35
36 39 Demyttenaere, K, Bruffaerts R, Posada-Villa J, Gasquet I, *et al.* Prevalence, severity, and
37 unmet need for treatment of mental disorders in the World Health Organization World
38 Mental Health Surveys. *JAMA* 2004;**291**:2581–90.
39
40
41
42
43 40 LaMontagne a D, Krnjacki L, Kavanagh a M, *et al.* Psychosocial working conditions in a
44 representative sample of working Australians 2001-2008: an analysis of changes in
45 inequalities over time. *Occup Environ Med* 2013;**70**:639–47. doi:10.1136/oemed-2012-
46 101171
47
48
49
50
51
52
53 41 Bourbonnais R, Brisson C, Vézina M. Long-term effects of an intervention on psychosocial
54 work factors among healthcare professionals in a hospital setting. *Occup Environ Med*
55 2011;**68**:479–86. doi:10.1136/oem.2010.055202
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Distribution of demographics (Phase 1; 2000-2002), working conditions (Phase 1 – Phase 2; 2007) and any psychotropic medication* between Phase 2 and 2013, the Helsinki Health Study, Finland (%) (*N*=3587)

	No medication <i>N</i> (%)	Medication <i>N</i> (%)	Mean DDDs (SD)†
Sex			
Women	2034 (71)	847 (29)	496.0 (773.3)
Men	545 (77)	161 (23)	487.1 (793.0)
Age			
40	632 (72)	247 (28)	587.5 (949.9)
45	636 (68)	298 (32)	537.6 (788.6)
50	664 (72)	259 (28)	429.5 (660.0)
55	627 (76)	196 (24)	391.2 (627.2)
60	20 (71)	8 (29)	666.2 (818.6)
Job control			
High-High	1075 (73)	402 (27)	453.2 (806.6)
High-Low	358 (71)	148 (29)	458.3 (793.9)
Low-High	300 (72)	117 (28)	541.5 (761.1)
Low-Low	846 (71)	341 (29)	543.1 (749.3)
Job demands			
Low-Low	554 (74)	304 (26)	411.6 (647.4)
Low-High	419 (72)	165 (28)	476.1 (716.0)
High-Low	432 (72)	169 (28)	463.7 (694.2)
High-High	844 (70)	370 (30)	585.1 (915.3)
Physical work load			
Low-Low	1718 (73)	633 (27)	500.2 (767.4)
Low-High	248 (869)	112 (31)	455.4 (679.6)
High-Low	255 (71)	104 (29)	428.1 (704.8)
High-High	358 (69)	159 (31)	543.4 (909.2)

*Participants with psychotropic medication purchases in three months preceding Phase 2 were excluded.

† Mean of defined daily doses (DDDs) and their standard deviations (SDs) in those who had psychotropic medication purchases during follow-up.

Table 2. Age and sex adjusted hazard ratios (HRs) and their 95% confidence intervals (95% CIs) for associations of changes in working conditions between Phase 1 (2000-2002) and Phase 2 (2007) and subsequent psychotropic medication between Phase 2 and the end of 2013, the Helsinki Health Study, Finland

	Any psychotropic (N=3587)			Antidepressants (N06A) (N=3660)			Anxiolytics (N05B) (N=3867)			Sedatives and hypnotics (N05C) (N=3808)		
	N (cases)	HR	95% CI	N (cases)	HR	95% CI	N (cases)	HR	95% CI	N (cases)	HR	95% CI
Job control												
High-High	1477 (402)	1.00	Reference	1499 (264)	1.00	Reference	1573 (102)	1.00	Reference	1559 (245)	1.00	Reference
High-Low	506 (148)	1.08	0.90-1.31	518 (95)	1.04	0.82-1.32	542 (43)	1.22	0.86-1.74	532 (94)	1.13	0.89-1.43
Low-High	417 (117)	1.03	0.84-1.27	425 (80)	1.06	0.83-1.36	457 (27)	0.90	0.59-1.38	449 (91)	1.33	1.04-1.69
Low-Low	1187 (341)	1.08	0.94-1.25	1218 (244)	1.18	0.99-1.41	1295 (113)	1.37	1.05-1.79	1268 (205)	1.03	0.86-1.24
Job demands												
Low-Low	1188 (304)	1.00	Reference	1208 (205)	1.00	Reference	1267 (83)	1.00	Reference	1254 (185)	1.00	Reference
Low-High	584 (165)	1.09	0.90-1.32	598 (117)	1.10	0.88-1.38	632 (45)	1.05	0.73-1.52	619 (108)	1.20	0.94-1.52
High-Low	601 (169)	1.09	0.91-1.32	610 (106)	1.01	0.80-1.27	649 (41)	0.96	0.66-1.39	639 (110)	1.16	0.92-1.47
High-High	1214 (370)	1.22	1.04-1.42	1244 (255)	1.20	1.00-1.45	1319 (116)	1.33	1.00-1.76	1296 (232)	1.21	0.99-1.47
Physical work load												
Low-Low	2351 (633)	1.00	Reference	2390 (423)	1.00	Reference	2508 (168)	1.00	Reference	2480 (382)	1.00	Reference
Low-High	360 (112)	1.17	0.96-1.43	371 (78)	1.17	0.92-1.49	400 (26)	1.09	0.74-1.62	384 (74)	1.32	1.04-1.69
High-Low	359 (104)	1.07	0.87-1.32	369 (63)	0.93	0.71-1.21	396 (30)	0.95	0.63-1.44	398 (80)	1.25	0.96-1.60
High-High	517 (159)	1.17	0.98-1.39	530 (119)	1.30	1.06-1.59	563 (61)	1.66	1.24-2.23	546 (99)	1.22	0.98-1.52


Note: Participants with psychotropic medication purchases in question (the medication groups were not mutually exclusive) in three months preceding Phase 2 were excluded.

Table 3. Age and sex adjusted hazard ratios (HRs) and their 95% confidence intervals (95% CIs) for associations of changes in working conditions between Phase 1 (2000-2002) and Phase 2 (2007) and subsequent psychotropic medication between Phase 2 and the end of 2013, the Helsinki Health Study, Finland

	Any psychotropic (N=3587)			Antidepressants (N06A) (N=3660)			Anxiolytics (N05B) (N=3867)			Sedatives and hypnotics (N05C) (N=3808)		
	N (cases)	HR	95% CI	N (cases)	HR	95% CI	N (cases)	HR	95% CI	N (cases)	HR	95% CI
Job control												
High-High	1477 (402)	0.92	0.80-1.07	1499 (264)	0.85	0.71-1.01	1573 (102)	0.73	0.56-0.96	1559 (245)	0.97	0.81-1.17
High-Low	506 (148)	1.00	0.82-1.21	518 (95)	0.88	0.70-1.12	542 (43)	0.89	0.63-1.27	532 (94)	1.09	0.86-1.40
Low-High	417 (117)	0.95	0.77-1.18	425 (80)	0.90	0.70-1.16	457 (27)	0.66	0.43-1.00	449 (91)	1.29	1.00-1.65
Low-Low	1187 (341)	1.00	Reference	1218 (244)	1.00	Reference	1295 (113)	1.00	Reference	1268 (205)	1.00	Reference
Job demands												
Low-Low	1188 (304)	0.82	0.71-0.96	1208 (205)	0.83	0.69-1.00	1267 (83)	0.75	0.57-1.00	1254 (185)	0.83	0.68-1.01
Low-High	584 (165)	0.90	0.75-1.08	598 (117)	0.91	0.73-1.14	632 (45)	0.79	0.56-1.12	619 (108)	0.99	0.79-1.25
High-Low	601 (169)	0.90	0.75-1.08	610 (106)	0.84	0.67-1.05	649 (41)	0.72	0.50-1.03	639 (110)	0.96	0.77-1.21
High-High	1214 (370)	1.00	Reference	1244 (255)	1.00	Reference	1319 (116)	1.00	Reference	1296 (232)	1.00	Reference
Physical work load												
Low-Low	2351 (633)	0.85	0.72-1.02	2390 (423)	0.77	0.63-0.95	2508 (168)	0.60	0.45-0.81	2480 (382)	0.82	0.66-1.03
Low-High	360 (112)	0.91	0.71-1.17	371 (78)	0.90	0.68-1.20	400 (26)	0.66	0.43-1.02	384 (74)	1.09	0.81-1.46
High-Low	359 (104)	1.00	0.78-1.27	369 (63)	0.72	0.53-0.98	396 (30)	0.57	0.36-0.90	398 (80)	1.03	0.76-1.39
High-High	517 (159)	1.00	Reference	530 (119)	1.00	Reference	563 (61)	1.00	Reference	546 (99)	1.00	Reference

Note: Participants with psychotropic medication purchases in question (the medication groups were not mutually exclusive) in three months preceding Phase 2 were excluded.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Survival curves for any psychotropic medication by changes in job control

152x101mm (300 x 300 DPI)

view only




Survival curves for any psychotropic medication by changes in job demands

152x101mm (300 x 300 DPI)

view only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Caption : Survival curves for any psychotropic medication by changes in physical working conditions

152x101mm (300 x 300 DPI)

view only

BMJ Open: first published as 10.1136/bmjopen-2016-015573 on 12 July 2017. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

Appendix 1

1 N06A Antidepressants

- 1.1 N06AA Non-selective monoamine reuptake inhibitors
- 1.2 N06AB Selective serotonin reuptake inhibitors
- 1.3 N06AF Monoamine oxidase inhibitors, non-selective
- 1.4 N06AG Monoamine oxidase A inhibitors
- 1.5 N06AX Other antidepressants

2 N05B Anxiolytics

- 2.1 N05BA Benzodiazepine derivatives
- 2.2 N05BB Diphenylmethane derivatives
- 2.3 N05BC Carbamates
- 2.4 N05BD Dibenzo-bicyclo-octadiene derivatives
- 2.5 N05BE Azaspirodecanedione derivatives
- 2.6 N05BX Other anxiolytics



3 N05C Hypnotics and sedatives



- 3.1 N05CA Barbiturates, plain
- 3.2 N05CB Barbiturates, combinations
- 3.3 N05CC Aldehydes and derivatives
- 3.4 N05CD Benzodiazepine derivatives
- 3.5 N05CE Piperidinedione derivatives
- 3.6 N05CF Benzodiazepine related drugs
- 3.7 N05CH Melatonin receptor agonists
- 3.8 N05CM Other hypnotics and sedatives
- 3.9 N05CX Hypnotics and sedatives in combination, excluding barbiturates

Appendix 2.

Smoothed scatter plots of Schoenfeld residuals against explanatory variables


Any psychotropic – change in job control








1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Any psychotropic – change in job demands







1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





BMJ Open: first published as 10.1136/bmjopen-2016-015573 on 12 July 2017. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.



Any psychotropic – change in physical working conditions



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	page	Recommendation
Title and abstract	1	p1	(a) Indicate the study's design with a commonly used term in the title or the abstract
		p2	(b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction			
Background/rationale	2	p4-5	Explain the scientific background and rationale for the investigation being reported
Objectives	3	p5	State specific objectives, including any prespecified hypotheses
Methods			
Study design	4	p5-6	Present key elements of study design early in the paper
Setting	5	p5-6	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	p5-6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up
			<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls
			<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants
			(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed
			<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	p6-8	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	p6-8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	p5-6	Describe any efforts to address potential sources of bias
Study size	10	p5-6	Explain how the study size was arrived at
Quantitative variables	11	p6-8	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	p8-9	(a) Describe all statistical methods, including those used to control for confounding
		p8-9	(b) Describe any methods used to examine subgroups and interactions
		p6	(c) Explain how missing data were addressed
		p5-6	(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed
			<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed
			<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy
		NA	(e) Describe any sensitivity analyses

Continued on next page

Results			
Participants	13*	p5-6	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
		p5-6	(b) Give reasons for non-participation at each stage
		considered	(c) Consider use of a flow diagram
Descriptive data	14*	p9+Table 1	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders
		p9	(b) Indicate number of participants with missing data for each variable of interest
		p8-9	(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data	15*	Tables	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time
			<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure
			<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	p10+Tables 2-3	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
		p7-8	(b) Report category boundaries when continuous variables were categorized
			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	p9	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion			
Key results	18	p10-11	Summarise key results with reference to study objectives
Limitations	19	p12-14	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	p14	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	p13	Discuss the generalisability (external validity) of the study results
Other information			
Funding	22	p1	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Changes in psychosocial and physical working conditions and psychotropic medication in ageing public sector employees: a record-linkage follow-up study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015573.R2
Article Type:	Research
Date Submitted by the Author:	24-May-2017
Complete List of Authors:	Kouvonen, Anne; University of Helsinki, Social Research; SWPS University of Social Sciences and Humanities, Faculty in Wroclaw Mänty, Minna; Helsinki University, Department of Public Health Lallukka, Tea; Finnish Institute of Occupational Health, Pietilainen, Olli; University of Helsinki, Hjelt Institute, Department of Public Health Lahelma, Eero; University of Helsinki, Department of Public Health Rahkonen, Ossi; University of Helsinki, Department of Public Health
Primary Subject Heading:	Occupational and environmental medicine
Secondary Subject Heading:	Epidemiology
Keywords:	MENTAL HEALTH, longitudinal studies, work stress

SCHOLARONE™
Manuscripts

Only

1
2
3 **Changes in psychosocial and physical working conditions and**
4
5
6 **psychotropic medication in ageing public sector employees: a record-**
7
8
9 **linkage follow-up study**
10

11
12
13
14
15 Anne Kouvonen,^{1,2,3} Minna Mänty,⁴ Tea Lallukka,^{4,5} Olli Pietiläinen,⁴ Eero Lahelma,⁴ Ossi
16
17 Rahkonen⁴
18
19

20
21
22 ¹Faculty of Social Sciences, University of Helsinki, Helsinki, Finland
23

24 ²SWPS University of Social Sciences and Humanities in Wroclaw, Wroclaw, Poland
25

26 ³Administrative Data Research Centre (Northern Ireland), Centre for Public Health, Queen's
27
28 University Belfast, Belfast, UK
29

30 ⁴Department of Public Health, University of Helsinki, Helsinki, Finland
31

32 ⁵Finnish Institute of Occupational Health, Helsinki, Finland
33
34
35
36

37 *Address for correspondence: Dr Anne Kouvonen, Department of Social Research, P.O. Box 54,
38
39 00014 University of Helsinki, Finland.
40

41
42 Telephone: +358 50 4487113; Email: anne.kouvonen@helsinki.fi
43
44

45 Manuscript statistics: 240 words in Abstract, 3308 words in text, 41 references, 3 Tables, 3 Figures
46
47

48 **Funding**

49

50
51 This work was supported by the Finnish Work Environment Fund (grant 112231), the Academy of
52
53 Finland (grants 1129225, 1257362, 1294514) and the University of Helsinki. AK was supported by
54
55 the Economic and Social Research Council (ESRC) (grant ES/L007509/1). MM was supported by
56
57
58
59
60

1
2
3 the Finnish Work Environment Fund (grant 115182) and the Juho Vainio Foundation. TL was
4 supported by the Academy of Finland (grant 287488).
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Abstract

Objectives: To investigate whether changes in psychosocial and physical working conditions are associated with subsequent psychotropic medication in ageing employees.

Methods: Data were from the Helsinki Health Study, a cohort study of Finnish municipal employees, aged 40-60 years at Phase 1 (2000-2002). Changes in psychosocial and physical working conditions were measured between Phase 1 and Phase 2 (2007). Survey data were longitudinally linked to data on prescribed, reimbursed psychotropic medication purchases (ATC) obtained from the registers of the Social Insurance Institution of Finland between the Phase 2 survey and December 2013 (N=3587; 80% women). Outcomes were any psychotropic medication; antidepressants (N06A); anxiolytics (N05B); and sedatives and hypnotics (N05C). Cox regression analyses were performed.

Results: During the follow-up 28% of the participants were prescribed psychotropic medication. Repeated exposures to low job control, high job demands and high physical work load were associated with an increased risk of subsequent antidepressant and anxiolytic medication. Increased and repeated exposure to high physical work load, increased job control and repeated high job demands were associated with subsequent sedative and hypnotic medication. Age and sex adjusted hazard ratios varied from 1.18 to 1.66. Improvement in job control was associated with a lower risk of anxiolytic, but with a higher risk of sedatives and hypnotic medication. Decreased physical work load was associated with a lower risk of antidepressant and anxiolytic medication.

Conclusion: Improvement in working conditions could lower the risk of mental ill-health indicated by psychotropic medication.

Keywords: mental health; longitudinal studies; work stress

1
2
3 **Abbreviations:** ATC, Anatomical Therapeutic Chemical; BMI, body mass index; CI, confidence
4 interval; DDD, defined daily dose; HR, hazard ratio; WHO, World Health Organization
5
6
7
8
9

10 **Strengths and limitations of this study**

- 13 • Unlike previous studies, we were able to examine changes in both psychosocial and physical
14 working conditions.
- 15 • Data were derived from a well characterised occupational cohort which was
16 deterministically linked to administrative medication records.
- 17 • The use of register-based medication data allowed us to remove the prevalent cases and
18 helped avoid the problems related to use of self-report measures such as recall and common
19 method bias.
- 20 • Due to relatively long interval between the two working conditions measurements, the study
21 could have underestimated the effect of changing working conditions on subsequent
22 psychotropic medication.
- 23 • We did not have information about the clinical indication the examined medication was
24 prescribed for.
- 25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Mental ill-health is a growing concern in working populations.[1] Adverse working conditions have been proposed as potentially modifiable risk factors for mental ill-health.[2] Indeed, there is evidence that exposure to adverse psychosocial working conditions including low job control and high job demands, are associated with an increased risk of mental ill-health.[3–7] However, the majority of earlier studies have measured both exposure and outcome using self-reports, which can lead to inflated associations and common method bias.[8] Other studies have avoided these problems by using register-based outcomes such as psychotropic medication, which is a commonly used marker of mental ill-health in a population.[9–14]

Most of the earlier studies have assessed exposure to adverse working conditions only at one time point, and there is a paucity of large-scale studies examining the association between changes in psychosocial working conditions and mental ill-health. Of a few studies that have separately assessed the effects of changes in job control and job demands on mental ill-health, three found that adverse changes in job demands had a stronger effect on the risk of self-reported mental ill-health than adverse changes in job control, whereas positive changes in these domains did not result in improvement in mental health.[5,15,16] In a recent study within-person increase in job control was associated with better self-reported mental health;[17] and in another study both improvements and deterioration in job demands and job control predicted change in mental health.[18] However, studies assessing the association between changes in job control and job demands and a more objective measure of mental ill-health, such as recorded psychotropic medication, are lacking.

Moreover, psychosocial working conditions have dominated discussion about the work-related determinants of poor mental health, even though there is evidence that also physical working

1
2
3 conditions are associated with mental ill-health. In the present cohort, increased and repeated
4 exposure to repetitive movements and repeated exposure to awkward postures and rotation of back
5 was associated with an increased likelihood of common mental disorders,[16] desktop work was
6 associated with purchases of sleeping pills among women,[19] and computer work was a risk factor
7 for disability retirement due to mental causes.[20] In another study deteriorating physical working
8 conditions increased perceived mental strain.[21] A review of the impact of working environment
9 on mood disorders discussed the potential mechanisms; however actual studies conducted in
10 employee cohorts were rare.[22] In a study among blue-collar workers exposure to noise intensified
11 anxiety and depression in women.[23]

12
13
14 We set out this study to examine the associations between changes in psychosocial and physical
15 working conditions and subsequent psychotropic medication.

16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

METHODS

Data

The data came from the Helsinki Health Study, which is a cohort study designed to investigate social and work-related determinants of health and well-being.[24] The target population is the staff of the City of Helsinki, Finland. Phase 1 questionnaire surveys were collected in 2000, 2001 and 2002 among employees turning 40, 45, 50, 55 or 60 each year (N=8960, response rate 67%; 80% of participants women). Phase 2 survey data were collected in 2007 (N=7332, response rate 83%).

Earlier non-response analysis showed that the participants broadly represent the target population.[24] Survey data were linked to national records using a unique personal identification number for those respondents who had given written consent for the linkage (74%; N=6498).

1
2
3 Consenting for the data linkage followed a similar pattern as the non-response, except that men
4
5 provided consent slightly more often than women.[24,25]
6
7

8
9
10 In the present study, of those who consented to linkage, only participants who were still employed
11
12 at Phase 2 were included (N=4207). Men, manual workers and those who reported common mental
13
14 disorders at Phase 1 had slightly more often left the employment between the two phases (all *p*
15
16 values < 0.01, data not shown). Because of the age structure of the cohort, the majority (86%) of
17
18 those who replied at Phase 2 and stated that they were not employed, had retired.
19

20
21
22 In addition, we excluded those with purchases of psychotropic medication in three months
23
24 preceding Phase 2 (n=337 for any psychotropic medication). Finally, we excluded those participants
25
26 who had missing values for any of the study variables (n=283). The exclusions resulted in a final
27
28 analytic sample of 3587 participants for the analyses examining any psychotropic medication.
29
30
31

32 33 34 **Ethics**

35
36
37
38 The Helsinki Health Study protocol was approved by the Ethics Committees of the Department of
39
40 Public Health, University of Helsinki, and the health authorities of the City of Helsinki. The study
41
42 conformed to the principles embodied in the Declaration of Helsinki.
43
44
45

46 47 48 **Measurements**

49 50 51 52 53 **Working conditions**

1
2
3 We used a version of Karasek's Job Content Questionnaire[26] to measure job control and job
4 demands. Job control was assessed by nine and job demands by five items. Job control scale
5 included items measuring skill discretion and decision authority. Job demands items assessed
6 workload and work pace. Missing values were replaced by item modes for those having responded
7 to at least eight job control and four job demands items, respectively. Job control and job demands
8 were both dichotomised at the median.[9,27]
9

10
11
12
13
14
15
16
17
18 *Physical work load*, that is, uncomfortable postures, repetitive trunk rotation, repetitive movements,
19 heavy physical exertion and lifting and carrying heavy loads, was assessed with an 18-item
20 instrument developed at the Finnish Institute of Occupational Health.[28] Missing values were
21 replaced by item modes for those having responded to at least fourteen items. Factor analysis
22 showed that the questions loaded on three factors, of which the first one was interpreted to best
23 measure physical work load. The items with the largest positive standardised scoring coefficients
24 were: awkward working positions; rotation of the back; repetitive movements; and heavy physical
25 effort or lifting and carrying heavy loads. Physical work load factor score was dichotomised at the
26 highest quartile.[29]
27
28
29
30
31
32
33
34
35
36
37
38
39

40 Changes in psychosocial and physical working conditions were measured by a four-category
41 variable for each of the three exposure variables: (i) repeated low exposure (low exposure at Phase
42 1 and low exposure at Phase 2); (ii) increased exposure (low exposure at Phase 1 and high exposure
43 at Phase 2); (iii) decreased exposure (high exposure at Phase 1 and low exposure at Phase 2); (iv)
44 repeated high exposure (high exposure at Phase 1 and high exposure at Phase 2).[30]
45
46
47
48
49
50
51

52 53 54 **Psychotropic medication** 55 56 57 58 59 60

1
2
3 Data on psychotropic medication were derived from the Finnish Prescription Register. This register
4 is maintained by the Social Insurance Institution and it includes records of all prescribed
5 psychotropic medication purchases reimbursed to Finnish residents in non-institutional settings. For
6 each dispensed drug, the record includes the dispensing date, the WHO Anatomical Therapeutic
7 Chemical (ATC) code, and the quantity prescribed and purchased as the number of defined daily
8 doses (DDDs).[31] We extracted information on all purchases of antidepressants, anxiolytics,
9 sedatives and hypnotics (ATC-codes N06A, N05B and N05C, respectively; see Appendix 1) in our
10 analytic sample, following Phase 2 survey date (index date) during the follow-up until December
11 31, 2013. Dates of deaths were retrieved from Statistics Finland (the Causes of Death Register).
12
13
14
15
16
17
18
19
20
21
22
23
24

25 **Covariates**

26
27
28
29 All covariates were survey-based and from Phase 1. We measured age, sex and marital status
30 (married/cohabiting vs. other). Moreover, we measured current smoking (yes vs. no), binge
31 drinking (six or more units of alcohol on one occasion once a month or more often), low physical
32 activity (less than 14 metabolic equivalent hours per week) and body mass index, which was
33 categorised as non-obese ($\leq 30 \text{ kg/m}^2$) and obese ($>30 \text{ kg/m}^2$).
34
35
36
37
38
39
40
41
42

43 **Statistical analysis**

44
45
46 The associations between sex, age and psychotropic medication during the follow-up were first
47 analysed using the Chi-square test. Cox proportional hazard models were fitted to examine the
48 association between change in psychosocial and physical working conditions between Phase 1 and
49 Phase 2 and subsequent psychotropic medication during the follow-up. We estimated hazard ratios
50 (HRs) and their 95% confidence intervals (95% CIs) for psychotropic medication by changes in
51 each working condition by first controlling for age and sex; then further controlling for marital
52
53
54
55
56
57
58
59
60

1
2
3 status, smoking, binge drinking, low physical activity, and obesity. In the first analysis, for each
4
5 working condition, the reference group was the most favourable working condition (i.e. repeated
6
7 high control, repeated low demands, and repeated high physical work load, respectively). To
8
9
10 examine the effects of positive changes in working conditions, we conducted an additional analysis
11
12 using the least favourable working condition as the reference group. The follow-up began from the
13
14 date of the Phase 2 survey response and ended at the first record of the psychotropic medication
15
16 purchase, death, or on 31 December, 2013, whichever came first.
17
18

19
20 We conducted the Therneau-Grambsch nonproportional hazards test, complementing it with the
21
22 smoothed scatter plot of Schoenfeld residuals against explanatory variables. The visual inspection
23
24 of the scatter plots supports the interpretation that the proportional hazards assumption was met.
25
26 The scatter plots for any psychotropic medication are presented in Appendix 2. Moreover, the
27
28 interaction terms between each working condition and logarithm of the follow-up period for any
29
30 psychotropic medication as well as for each medication group were non-significant (all $p > 0.05$),
31
32 further confirming that the proportional-hazards assumption was justified
33
34

35
36 None of the gender interactions were statistically significant (all interaction terms sex*working
37
38 condition $p > 0.05$); we therefore analysed women and men together, adjusting for gender.
39
40

41
42
43 The analyses were conducted with SAS 9.4 (SAS Institute, Inc., Cary, North Carolina) and R.
44
45
46
47

48 RESULTS

49
50
51
52

53 **Table 1** shows the distribution of the key study variables by any prescribed psychotropic
54
55 medication during follow-up. The mean age at baseline was 47.5 years. A total of 1008 participants
56
57 (28%) recorded at least one purchase of prescribed psychotropic medication during the mean
58
59
60

1
2
3 follow-up of 5.0 years. Psychotropic medication was more prevalent among women (29%) than
4 among men (23%). Nineteen percent of the participants received antidepressant medication during
5 the follow-up. The corresponding figures for anxiolytics and for hypnotics/sedatives were 7% and
6
7
8
9
10 17%, respectively.

11
12
13
14 As displayed in **Table 2**, after adjustment for age and sex, repeated high job demands (HR=1.22,
15 95% CI: 1.04-1.42) were associated with any psychotropic medication. The association between
16 repeated high physical work load and any psychotropic medication was marginally statistically
17 significant (HR=1.17, 95% CI: 0.98-1.39). Figures 1, 2 and 3 show survival curves for any
18 psychotropic medication by changes in working conditions.
19
20
21
22
23
24
25

26 When the groups of psychotropic medication were examined separately, repeated high job demands
27 (HR=1.20, 95% CI: 1.00-1.45) and repeated high physical work load (HR=1.30, 95% CI: 1.06-1.59)
28 were associated with subsequent antidepressant medication, whereas repeated low job control (1.37,
29 95% CI: 1.05-1.79), repeated high demands (HR=1.33, 95% CI: 1.00-1.76), and repeated high
30 physical work load (HR=1.66, 95% CI: 1.24-2.23) were associated with subsequent anxiolytic
31 medication. Increased job control and increased physical work load were associated with
32 subsequent sedative and hypnotic medication. Repeated high demands and repeated physical work
33 load showed associations with subsequent sedative and hypnotic medication. Further adjustment for
34 marital status, health behaviours, and obesity only marginally changed the HRs (data not shown).
35
36
37
38
39
40
41
42
43
44
45

46 We additionally tested whether favourable change in working conditions was associated with a
47 lower risk of psychotropic medication, by using the least favourable working conditions as
48 reference categories (Table 3). Compared to repeatedly low job control, increased job control was
49 associated with a lower risk of anxiolytic, but a higher risk of sedative and hypnotic medication.
50
51
52
53
54
55
56
57
58
59
60 Compared to repeatedly high physical work load, decreased physical load was associated with a
lower risk of subsequent antidepressant and anxiolytic medication.

DISCUSSION

In this study, repeated and increased exposure to adverse psychosocial and physical working conditions was associated with subsequent psychotropic medication. It is notable that we found similar associations for both types of working conditions. However, the associations between adverse working conditions and subsequent psychotropic medication were modest. This is expected: the aetiology of mental disorders – the main indication for psychotropic medication - is complex and multifactorial, involving multiple social, psychological and biological factors.[32] Exposure to adverse working conditions or a positive or negative change in them is only one such factor.

Compared to employees with repeated low job demands, the employees whose job demands had increased had a higher risk of purchasing any psychotropic medication as well as antidepressant medication. Moreover, repeated exposure to high job demands was associated with subsequent antidepressant and anxiolytic medication; with anxiolytics showing a slightly stronger association. Antidepressant and anxiolytic medications are likely to reflect depression and other mental disorders such as anxiety disorders (including generalized anxiety disorder and panic disorder). A number of previous studies have shown a link between high job demands and an increased risk of mental ill-health.[3,15,16,33]

Previous results for job control have been mixed. In a meta-analytic review published in 2006 low decision latitude predicted common mental disorders.[3] In terms of more objective outcomes, null results have been reported for psychotropic prescriptions,[13,34] whereas one previous study showed an association between high decision authority and an elevated risk of hospital admissions due to mental disorders.[35] In our study increased job control was associated with a subsequent

1
2
3 sedative and hypnotic medication. In a previous study, active jobs, that is, those with high levels of
4 control and demands, were associated with a higher risk of depression and burnout.[36] It is
5 possible that increased decision authority and high responsibility may become a burden for some
6 employees. It is also possible that high job control reflects not only working conditions but also
7 characteristics of a generally more active employee with a higher likelihood of seeking
8 treatment.[35]

9
10
11
12 The result that increased job control was associated with a lower risk of anxiolytic, but a higher risk
13 of sedative and hypnotic medication seems conflicting and is difficult to explain. It is possible that
14 a switch between some anxiolytic benzodiazepine and hypnotic benzodiazepine could confound
15 these associations. Unfortunately we had no information about the indication of the medication use.

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
When comparing to the least favourable working conditions, increased job control was associated
with a lower risk of anxiolytic medication; and decreased physical load was associated with a lower
risk of antidepressant and anxiolytic medication. Two earlier studies did not find an association
between favourable changes in psychosocial working conditions and a decreased risk of subsequent
mental ill-health.[15,37] However, in one previous study both improvements and deterioration in
job demands and control were associated with corresponding improvements or deterioration in
mental health,[18] and in another study decrease of job strain was associated with a lower
likelihood of repeated insomnia symptoms.[38]

Most of the earlier studies have investigated only psychosocial working conditions. In the present
study repeatedly high and increased physical work load were associated with subsequent
psychotropic medication. In fact, the strongest association (HR=1.66 for anxiolytic medication)
between working conditions and psychotropic medication was found for repeated high physical

1
2
3 workload. Our findings thus support the earlier findings in the present and other cohorts, which
4
5 have shown associations between exposure to adverse physical working conditions and common
6
7 mental disorders,[16] disability retirement due to mental disorders,[20] purchases of sleeping
8
9 pills,[19] and perceived mental strain.[21]
10

11 12 13 **Methodological considerations**

14
15
16
17
18 Certain limitations need to be acknowledged. First, because of the relatively long interval between
19
20 the two working conditions measurements, this study could have underestimated the effect of
21
22 changing working conditions on subsequent medication. Moreover, working conditions could have
23
24 changed several times during the follow-up; this could have resulted in more conservative effect
25
26 sizes.
27

28
29
30 Second, we were unable to assess the magnitude of change in working conditions; the use of these
31
32 crude measures only assessed whether a participant had moved from one category to another.

33
34 Furthermore, we did not have information about the prior duration of exposure to adverse working
35
36 conditions. The use of thresholds may have led to underestimates of true effects of changing
37
38 working conditions.[5]
39

40
41
42
43 Third, we did not have information about clinical indication the examined medication was
44
45 prescribed for. Even if psychotropic medication is a recommended treatment for a number of mental
46
47 disorders and prescription data derived from official registers can therefore be considered as a proxy
48
49 for mental disorders requiring treatment, these medications are prescribed also for other conditions.
50

51
52 On the other hand, it has been shown that mental disorders are underdiagnosed and
53
54 undertreated.[39]
55
56
57
58
59
60

1
2
3 Fourth, we did not have information about the discontinuation and the pattern of use of
4
5 psychotropic medication. Even if a participant had purchased the prescribed medication from the
6
7 pharmacy, they could have discontinued the use. Discontinuation of psychotropic drugs can lead to
8
9 different meanings: the discontinuation of antidepressants can be associated with either side effects
10
11 or lack of follow-up controls, whereas sporadic use of anxiolytics and hypnotics can be due to
12
13 temporary discomfort. Unfortunately we had no information about the pattern of use of the
14
15 prescribed medication, that is, whether the medication was used sporadically or continuously.
16
17
18
19

20
21 Fifth, participants who left employment between Phase 1 and Phase 2 were not included in the
22
23 study. It has been suggested that the age-related health selection may result in a more resilient older
24
25 worker population [37]. A healthy worker effect may thus have led to underestimation of the
26
27 associations.
28
29
30
31

32 Finally, even if the data consisted of a broad range of both manual and non-manual occupations, the
33
34 study population was not a representative sample of the total working population. Because the
35
36 Finnish public sector workforce is female-dominated, women were over-represented also in this
37
38 sample. Moreover, the present sample consisted only of ageing employees with stable and secure
39
40 long-term employment and working in the capital city. Therefore the results may be generalisable,
41
42 with caution, to the Finnish municipal sector, but might not be generalisable to other age groups,
43
44 cohorts and industries.
45
46
47
48

49 Despite of these limitations, the present study has a number of strengths. The main strengths are the
50
51 use of prospective design which enabled us to examine changes in working conditions, data derived
52
53 from a well characterised occupational cohort, minor attrition, deterministic linkage to
54
55 administrative medication records, and an ability to examine changes in both psychosocial and
56
57
58
59
60

1
2
3 physical working conditions. Psychotropic medication data were based on a physician's prescription
4 and cover virtually all reimbursed psychotropic prescriptions for the analytic sample. The use of
5 register-based medication data allowed us to remove the prevalent cases and helped avoid the
6
7 problems related to use of self-report measures such as recall and common method bias. Extensive
8
9 non-response analyses were available and showed only small non-participation bias. We were able
10
11 to adjust for a number of important covariates such as health behaviours and obesity.
12
13
14

15 16 17 18 **CONCLUSION** 19

20
21
22
23 To conclude, this study showed that established psychosocial risk factors such as repeated exposure
24
25 to high job demands and low control are associated with subsequent psychotropic medication in
26
27 midlife and older employees. Furthermore, the results showed that also repeated and increased
28
29 exposure to adverse physical working conditions may contribute to subsequent psychotropic
30
31 medication. Identification of these potentially modifiable risk factors implies possibilities for
32
33 prevention.[40] Theory-based, organisationally focused interventions to tackle adverse working
34
35 conditions might be beneficial. Evidence for this is emerging. An intervention study in Canadian
36
37 hospitals showed an intervention to reduce work stress was able to produce beneficial long-term
38
39 effects on hospital employees' emotional well-being, in particular through reducing professional
40
41 burnout.[41] However, well-designed randomized controlled trials with reliable and valid objective
42
43 indicators of working conditions are needed to reliably test whether intentional workplace
44
45 interventions can prevent employee mental ill-health.
46
47
48
49
50
51

52
53 **Conflicts of interest:** None declared
54

55
56
57 **Author contributions:**
58
59
60

1
2
3 All authors jointly designed and conceptualised the study. Anne Kouvonen directed the
4 implementation of the study, led all aspects of the work, and drafted the article. Anne Kouvonen
5 and Olli Pietiläinen performed the data analysis. Tea Lallukka, Eero Lahelma, Olli Pietiläinen and
6
7 Ossi Rahkonen contributed to acquisition of data. Minna Mänty, Tea Lallukka, Olli Pietiläinen,
8
9 Eero Lahelma and Ossi Rahkonen contributed to designing the study's analytic strategy,
10
11 interpreting findings, reviewing the article and revising it critically for important intellectual
12
13 content. All authors approved the manuscript's submission for publication.
14
15
16
17
18

19 **Data sharing statement:** No additional data available.
20
21

22 **Figure legends**

23
24
25
26 Figure 1. Survival curves for any psychotropic medication by changes in job control
27

28
29 Figure 2. Survival curves for any psychotropic medication by changes in job demands
30

31
32 Figure 3. Survival curves for any psychotropic medication by changes in physical working
33
34 conditions
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

- 1 OECD. Sick on the Job? Myths and Realities about Mental Health and Work. 2011.
doi:10.1787/9789264124523-en
- 2 LaMontagne AD, Martin A, Page KM, *et al.* Workplace mental health: developing an
integrated intervention approach. *BMC Psychiatry* 2014;**14**:131. doi:10.1186/1471-244X-14-
131
- 3 Stansfeld S, Candy B. Psychosocial work environment and mental health—a meta-analytic
review. *Scand J Work Environ Health* 2006;**32**:443–62. doi:10.5271/sjweh.1050
- 4 Nieuwenhuijsen K, Bruinvels D, Frings-Dresen M. Psychosocial work environment and
stress-related disorders, a systematic review. *Occup Med (Lond)* 2010;**60**:277–86.
doi:10.1093/occmed/kqq081
- 5 Smith PM, Bielecky A. The impact of changes in job strain and its components on the risk of
depression. *Am J Public Health* 2012;**102**:352–8. doi:10.2105/AJPH.2011.300376
- 6 Traweger C, Kinzl JF, Traweger-Ravanelli B, *et al.* Psychosocial factors at the workplace--
do they affect substance use? Evidence from the Tyrolean workplace study.
Pharmacoepidemiol Saf 2004;**13**:399–403. doi:10.1002/pds.955
- 7 Ngoundo-Mbongue TB, Niezborala M, Sulem P, *et al.* Psychoactive drug consumption:
Performance-enhancing behaviour and pharmacodependence in workers.
Pharmacoepidemiol Drug Saf 2005;**14**:81–9. doi:10.1002/pds.1006
- 8 Kolstad HA, Hansen ÅM, Kærgaard A, *et al.* Job strain and the risk of depression: Is
reporting biased? *Am J Epidemiol* 2011;**173**:94–102. doi:10.1093/aje/kwq318
- 9 Magnusson Hanson LL, Madsen IEH, Westerlund H, *et al.* Antidepressant use and

- 1
2
3 associations with psychosocial work characteristics. A comparative study of Swedish and
4 Danish gainfully employed. *J Affect Disord* 2013;**149**:38–45. doi:10.1016/j.jad.2012.08.023
5
6
7
8
9
10 Thielen K, Nygaard E, Rugulies R, *et al.* Job stress and the use of antidepressant medicine: a
11 3.5-year follow-up study among Danish employees. *Occup Environ Med* 2011;**68**:205–10.
12 doi:10.1136/oem.2010.057943
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 11 Virtanen M, Honkonen T, Kivimäki M, *et al.* Work stress, mental health and antidepressant
medication findings from the Health 2000 Study. *J Affect Disord* 2007;**98**:189–97.
doi:10.1016/j.jad.2006.05.034
- 12 D'Errico A, Cardano M, Landriscina T, *et al.* Workplace stress and prescription of
antidepressant medications: A prospective study on a sample of Italian workers. *Int Arch
Occup Environ Health* 2011;**84**:413–24. doi:10.1007/s00420-010-0586-3
- 13 Bonde JPE, Munch-Hansen T, Wieclaw J, *et al.* Psychosocial work environment and
antidepressant medication: a prospective cohort study. *BMC Public Health* 2009;**9**:262.
doi:10.1186/1471-2458-9-262
- 14 Lavigne E, Bourbonnais R. Psychosocial work environment, interpersonal violence at work
and psychotropic drug use among correctional officers. *Int J Law Psychiatry* 2010;**33**:122–9.
doi:10.1016/j.ijlp.2009.12.005
- 15 Stansfeld SA, Fuhrer R, Shipley MJ, *et al.* Work characteristics predict psychiatric disorder:
prospective results from the Whitehall II Study. *Occup Environ Med* 1999;**56**:302–7.
doi:10.1136/oem.56.5.302
- 16 Kouvonen A, Mänty M, Lallukka T, *et al.* Changes in psychosocial and physical working
conditions and common mental disorders. *Eur J Public Health* 2016;:ckw019.
doi:10.1093/eurpub/ckw019

- 1
2
3 17 Bentley RJ, Kavanagh A, Krnjacki L, *et al.* A longitudinal analysis of changes in job control
4 and mental health. *Am J Epidemiol* 2015;**182**:328–34. doi:10.1093/aje/kwv046
5
6
7
8 18 Strazdins L, D’Souza RM, Clements M, *et al.* Could better jobs improve mental health? A
9 prospective study of change in work conditions and mental health in mid-aged adults. *J*
10
11
12
13
14
15 19 Laaksonen M, Lallukka T, Lahelma E, *et al.* Working conditions and psychotropic
16 medication: a prospective cohort study. *Soc Psychiatry Psychiatr Epidemiol* 2012;**47**:663–70.
17
18
19
20
21
22 20 Lahelma E, Laaksonen M, Lallukka T, *et al.* Working conditions as risk factors for disability
23 retirement: a longitudinal register linkage study. *BMC Public Health* 2012;**12**:309.
24
25
26
27
28
29 21 Neupane S, Virtanen P, Luukkaala T, *et al.* A four-year follow-up study of physical working
30 conditions and perceived mental and physical strain among food industry workers. *Appl*
31
32
33
34
35
36
37 22 Woo J-M, Postolache TT. The impact of work environment on mood disorders and suicide:
38 Evidence and implications. *Int. J. Disabil. Hum. Dev.* 2008;**7**:185–200.
39
40
41
42 23 Melamed S, Luz J, Green MS. Noise exposure, noise annoyance and their relation to
43 psychological distress, accident and sickness absence among blue-collar workers--the Cordis
44
45
46
47
48
49 24 Lahelma E, Aittomäki A, Laaksonen M, *et al.* Cohort profile: The Helsinki Health Study. *Int*
50
51
52
53
54 25 Laaksonen M, Aittomäki A, Lallukka T, *et al.* Register-based study among employees
55 showed small nonparticipation bias in health surveys and check-ups. *J Clin Epidemiol*
56
57
58
59
60

- 2008;**61**:900–6. doi:10.1016/j.jclinepi.2007.09.010
- 26 Karasek R, Brisson C, Kawakami N, *et al.* The Job Content Questionnaire (JCQ): an instrument for internationally comparative assessments of psychosocial job characteristics. *J Occup Health Psychol* 1998;**3**:322–55. doi:10.1037/1076-8998.3.4.322
- 27 Rugulies R, Bültmann U, Aust B, *et al.* Psychosocial work environment and incidence of severe depressive symptoms: prospective findings from a 5-year follow-up of the Danish work environment cohort study. *Am J Epidemiol* 2006;**163**:877–87. doi:10.1093/aje/kwj119
- 28 Piirainen H, Hirvonen M, Elo AL. The Work and Health interview study 2003. Basic report. Helsinki: 2003.
- 29 Laaksonen M, Pitkäniemi J, Rahkonen O, *et al.* Work Arrangements, Physical Working Conditions, and Psychosocial Working Conditions as Risk Factors for Sickness Absence: Bayesian Analysis of Prospective Data. *Ann Epidemiol* 2010;**20**:332–8. doi:10.1016/j.annepidem.2010.02.004
- 30 Saastamoinen P, Laaksonen M, Lahelma E, *et al.* Changes in working conditions and subsequent sickness absence. *Scand J Work Environ Heal* 2014;**40**:82–8. doi:10.5271/sjweh.3379
- 31 WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2014. Oslo: 2013.
- 32 Tsuang MT, Bar JL, Stone WS, *et al.* Gene-environment interactions in mental disorders. *World Psychiatry* 2004;**3**:73–83.
- 33 Kivimäki M, Vahtera J, Kawachi I, *et al.* Psychosocial work environment as a risk factor for absence with a psychiatric diagnosis: an instrumental-variables analysis. *Am J Epidemiol* 2010;**172**:167–72. doi:10.1093/aje/kwq094

- 1
2
3 34 DeSanto Iennaco J, Cullen MR, Cantley L, *et al.* Effects of externally rated job demand and
4 control on depression diagnosis claims in an industrial cohort. *Am J Epidemiol*
5 2010;**171**:303–11. doi:10.1093/aje/kwp359
6
7
8
9
10 35 Joensuu M, Väänänen A, Koskinen A, *et al.* Psychosocial work environment and hospital
11 admissions due to mental disorders: A 15-year prospective study of industrial employees. *J*
12 *Affect Disord* 2010;**124**:118–25. doi:10.1016/j.jad.2009.10.025
13
14
15
16
17 36 Ahola K, Honkonen T, Kivimäki M, *et al.* Contribution of burnout to the association between
18 job strain and depression: the health 2000 study. *J Occup Env Med* 2006;**48**:1023–30.
19
20
21
22 37 Stansfeld SA, Shipley MJ, Head J, *et al.* Repeated job strain and the risk of depression:
23 longitudinal analyses from the Whitehall II study. *Am J Public Health* 2012;**102**:2360–6.
24 doi:10.2105/AJPH.2011.300589
25
26
27
28
29 38 Halonen JI, Lallukka T, Pentti J, *et al.* Change in Job Strain as A Predictor of Change in
30 Insomnia Symptoms: Analyzing Observational Data as A Non-randomized Pseudo-Trial.
31 *Sleep* 2016.
32
33
34
35
36 39 Demyttenaere, K, Bruffaerts R, Posada-Villa J, Gasquet I, *et al.* Prevalence, severity, and
37 unmet need for treatment of mental disorders in the World Health Organization World
38 Mental Health Surveys. *JAMA* 2004;**291**:2581–90.
39
40
41
42
43 40 LaMontagne a D, Krnjacki L, Kavanagh a M, *et al.* Psychosocial working conditions in a
44 representative sample of working Australians 2001-2008: an analysis of changes in
45 inequalities over time. *Occup Environ Med* 2013;**70**:639–47. doi:10.1136/oemed-2012-
46 101171
47
48
49
50
51
52
53 41 Bourbonnais R, Brisson C, Vézina M. Long-term effects of an intervention on psychosocial
54 work factors among healthcare professionals in a hospital setting. *Occup Environ Med*
55 2011;**68**:479–86. doi:10.1136/oem.2010.055202
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Distribution of demographics (Phase 1; 2000-2002), working conditions (Phase 1 – Phase 2; 2007) and any psychotropic medication* between Phase 2 and 2013, the Helsinki Health Study, Finland (%) (*N*=3587)

	No medication <i>N</i> (%)	Medication <i>N</i> (%)	Mean DDDs (SD)†
Sex			
Women	2034 (71)	847 (29)	496.0 (773.3)
Men	545 (77)	161 (23)	487.1 (793.0)
Age			
40	632 (72)	247 (28)	587.5 (949.9)
45	636 (68)	298 (32)	537.6 (788.6)
50	664 (72)	259 (28)	429.5 (660.0)
55	627 (76)	196 (24)	391.2 (627.2)
60	20 (71)	8 (29)	666.2 (818.6)
Job control			
High-High	1075 (73)	402 (27)	453.2 (806.6)
High-Low	358 (71)	148 (29)	458.3 (793.9)
Low-High	300 (72)	117 (28)	541.5 (761.1)
Low-Low	846 (71)	341 (29)	543.1 (749.3)
Job demands			
Low-Low	554 (74)	304 (26)	411.6 (647.4)
Low-High	419 (72)	165 (28)	476.1 (716.0)
High-Low	432 (72)	169 (28)	463.7 (694.2)
High-High	844 (70)	370 (30)	585.1 (915.3)
Physical work load			
Low-Low	1718 (73)	633 (27)	500.2 (767.4)
Low-High	248 (869)	112 (31)	455.4 (679.6)
High-Low	255 (71)	104 (29)	428.1 (704.8)
High-High	358 (69)	159 (31)	543.4 (909.2)

*Participants with psychotropic medication purchases in three months preceding Phase 2 were excluded.

† Mean of defined daily doses (DDDs) and their standard deviations (SDs) in those who had psychotropic medication purchases during follow-up.

Table 2. Age and sex adjusted hazard ratios (HRs) and their 95% confidence intervals (95% CIs) for associations of changes in working conditions between Phase 1 (2000-2002) and Phase 2 (2007) and subsequent psychotropic medication between Phase 2 and the end of 2013, the Helsinki Health Study, Finland

	Any psychotropic (N=3587)			Antidepressants (N06A) (N=3660)			Anxiolytics (N05B) (N=3867)			Sedatives and hypnotics (N05C) (N=3808)		
	N (cases)	HR	95% CI	N (cases)	HR	95% CI	N (cases)	HR	95% CI	N (cases)	HR	95% CI
Job control												
High-High	1477 (402)	1.00	Reference	1499 (264)	1.00	Reference	1573 (102)	1.00	Reference	1559 (245)	1.00	Reference
High-Low	506 (148)	1.08	0.90-1.31	518 (95)	1.04	0.82-1.32	542 (43)	1.22	0.86-1.74	532 (94)	1.13	0.89-1.43
Low-High	417 (117)	1.03	0.84-1.27	425 (80)	1.06	0.83-1.36	457 (27)	0.90	0.59-1.38	449 (91)	1.33	1.04-1.69
Low-Low	1187 (341)	1.08	0.94-1.25	1218 (244)	1.18	0.99-1.41	1295 (113)	1.37	1.05-1.79	1268 (205)	1.03	0.86-1.24
Job demands												
Low-Low	1188 (304)	1.00	Reference	1208 (205)	1.00	Reference	1267 (83)	1.00	Reference	1254 (185)	1.00	Reference
Low-High	584 (165)	1.09	0.90-1.32	598 (117)	1.10	0.88-1.38	632 (45)	1.05	0.73-1.52	619 (108)	1.20	0.94-1.52
High-Low	601 (169)	1.09	0.91-1.32	610 (106)	1.01	0.80-1.27	649 (41)	0.96	0.66-1.39	639 (110)	1.16	0.92-1.47
High-High	1214 (370)	1.22	1.04-1.42	1244 (255)	1.20	1.00-1.45	1319 (116)	1.33	1.00-1.76	1296 (232)	1.21	0.99-1.47
Physical work load												
Low-Low	2351 (633)	1.00	Reference	2390 (423)	1.00	Reference	2508 (168)	1.00	Reference	2480 (382)	1.00	Reference
Low-High	360 (112)	1.17	0.96-1.43	371 (78)	1.17	0.92-1.49	400 (26)	1.09	0.74-1.62	384 (74)	1.32	1.04-1.69
High-Low	359 (104)	1.07	0.87-1.32	369 (63)	0.93	0.71-1.21	396 (30)	0.95	0.63-1.44	398 (80)	1.25	0.96-1.60
High-High	517 (159)	1.17	0.98-1.39	530 (119)	1.30	1.06-1.59	563 (61)	1.66	1.24-2.23	546 (99)	1.22	0.98-1.52


Note: Participants with psychotropic medication purchases in question (the medication groups were not mutually exclusive) in three months preceding Phase 2 were excluded.

Table 3. Age and sex adjusted hazard ratios (HRs) and their 95% confidence intervals (95% CIs) for associations of changes in working conditions between Phase 1 (2000-2002) and Phase 2 (2007) and subsequent psychotropic medication between Phase 2 and the end of 2013, the Helsinki Health Study, Finland

	Any psychotropic (N=3587)			Antidepressants (N06A) (N=3660)			Anxiolytics (N05B) (N=3867)			Sedatives and hypnotics (N05C) (N=3808)		
	N (cases)	HR	95% CI	N (cases)	HR	95% CI	N (cases)	HR	95% CI	N (cases)	HR	95% CI
Job control												
High-High	1477 (402)	0.92	0.80-1.07	1499 (264)	0.85	0.71-1.01	1573 (102)	0.73	0.56-0.96	1559 (245)	0.97	0.81-1.17
High-Low	506 (148)	1.00	0.82-1.21	518 (95)	0.88	0.70-1.12	542 (43)	0.89	0.63-1.27	532 (94)	1.09	0.86-1.40
Low-High	417 (117)	0.95	0.77-1.18	425 (80)	0.90	0.70-1.16	457 (27)	0.66	0.43-1.00	449 (91)	1.29	1.00-1.65
Low-Low	1187 (341)	1.00	Reference	1218 (244)	1.00	Reference	1295 (113)	1.00	Reference	1268 (205)	1.00	Reference
Job demands												
Low-Low	1188 (304)	0.82	0.71-0.96	1208 (205)	0.83	0.69-1.00	1267 (83)	0.75	0.57-1.00	1254 (185)	0.83	0.68-1.01
Low-High	584 (165)	0.90	0.75-1.08	598 (117)	0.91	0.73-1.14	632 (45)	0.79	0.56-1.12	619 (108)	0.99	0.79-1.25
High-Low	601 (169)	0.90	0.75-1.08	610 (106)	0.84	0.67-1.05	649 (41)	0.72	0.50-1.03	639 (110)	0.96	0.77-1.21
High-High	1214 (370)	1.00	Reference	1244 (255)	1.00	Reference	1319 (116)	1.00	Reference	1296 (232)	1.00	Reference
Physical work load												
Low-Low	2351 (633)	0.85	0.72-1.02	2390 (423)	0.77	0.63-0.95	2508 (168)	0.60	0.45-0.81	2480 (382)	0.82	0.66-1.03
Low-High	360 (112)	0.91	0.71-1.17	371 (78)	0.90	0.68-1.20	400 (26)	0.66	0.43-1.02	384 (74)	1.09	0.81-1.46
High-Low	359 (104)	1.00	0.78-1.27	369 (63)	0.72	0.53-0.98	396 (30)	0.57	0.36-0.90	398 (80)	1.03	0.76-1.39
High-High	517 (159)	1.00	Reference	530 (119)	1.00	Reference	563 (61)	1.00	Reference	546 (99)	1.00	Reference

Note: Participants with psychotropic medication purchases in question (the medication groups were not mutually exclusive) in three months preceding Phase 2 were excluded.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Survival curves for any psychotropic medication by changes in job control

152x101mm (300 x 300 DPI)

view only




Survival curves for any psychotropic medication by changes in job demands

152x101mm (300 x 300 DPI)

view only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Caption : Survival curves for any psychotropic medication by changes in physical working conditions

152x101mm (300 x 300 DPI)

view only

BMJ Open: first published as 10.1136/bmjopen-2016-015573 on 12 July 2017. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

Appendix 1

1 N06A Antidepressants

- 1.1 N06AA Non-selective monoamine reuptake inhibitors
- 1.2 N06AB Selective serotonin reuptake inhibitors
- 1.3 N06AF Monoamine oxidase inhibitors, non-selective
- 1.4 N06AG Monoamine oxidase A inhibitors
- 1.5 N06AX Other antidepressants

2 N05B Anxiolytics

- 2.1 N05BA Benzodiazepine derivatives
- 2.2 N05BB Diphenylmethane derivatives
- 2.3 N05BC Carbamates
- 2.4 N05BD Dibenzo-bicyclo-octadiene derivatives
- 2.5 N05BE Azaspirodecanedione derivatives
- 2.6 N05BX Other anxiolytics



3 N05C Hypnotics and sedatives



- 3.1 N05CA Barbiturates, plain
- 3.2 N05CB Barbiturates, combinations
- 3.3 N05CC Aldehydes and derivatives
- 3.4 N05CD Benzodiazepine derivatives
- 3.5 N05CE Piperidinedione derivatives
- 3.6 N05CF Benzodiazepine related drugs
- 3.7 N05CH Melatonin receptor agonists
- 3.8 N05CM Other hypnotics and sedatives
- 3.9 N05CX Hypnotics and sedatives in combination, excluding barbiturates


Appendix 2.

Smoothed scatter plots of Schoenfeld residuals against explanatory variables


Any psychotropic – change in job control











Any psychotropic – change in job demands







1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Any psychotropic – change in physical working conditions




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Beta(t) for Physical working conditions: Low-High




Beta(t) for Physical working conditions: High-High



Beta(t) for Physical working conditions: High-High



Beta(t) for Sex



STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	page	Recommendation
Title and abstract	1	p1	(a) Indicate the study's design with a commonly used term in the title or the abstract
		p2	(b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction			
Background/rationale	2	p4-5	Explain the scientific background and rationale for the investigation being reported
Objectives	3	p5	State specific objectives, including any prespecified hypotheses
Methods			
Study design	4	p5-6	Present key elements of study design early in the paper
Setting	5	p5-6	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	p5-6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up
			<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls
			<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants
			(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed
			<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	p6-8	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	p6-8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	p5-6	Describe any efforts to address potential sources of bias
Study size	10	p5-6	Explain how the study size was arrived at
Quantitative variables	11	p6-8	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	p8-9	(a) Describe all statistical methods, including those used to control for confounding
		p8-9	(b) Describe any methods used to examine subgroups and interactions
		p6	(c) Explain how missing data were addressed
		p5-6	(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed
			<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed
	<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy		
	NA		(e) Describe any sensitivity analyses

Continued on next page

Results			
Participants	13*	p5-6	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
		p5-6	(b) Give reasons for non-participation at each stage
		considered	(c) Consider use of a flow diagram
Descriptive data	14*	p9+Table 1	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders
		p9	(b) Indicate number of participants with missing data for each variable of interest
		p8-9	(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data	15*	Tables	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time
			<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure
			<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	p10+Tables 2-3	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
		p7-8	(b) Report category boundaries when continuous variables were categorized
			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	p9	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion			
Key results	18	p10-11	Summarise key results with reference to study objectives
Limitations	19	p12-14	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	p14	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	p13	Discuss the generalisability (external validity) of the study results
Other information			
Funding	22	p1	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

Correction: *Changes in psychosocial and physical working conditions and psychotropic medication in ageing public sector employees: a record-linkage follow-up study*

Kouvonen A, Mänty M, Lallukka T, *et al.* Changes in psychosocial and physical working conditions and psychotropic medication in ageing public sector employees: a record-linkage follow-up study. *BMJ Open* 2017;7:e015573. doi: 10.1136/bmjopen-2016-015573.

This article was previously published with some errors.

In review of their article the authors found an error in the equation of their measurement of physical work load. In factor analysis, the items indicating physical work load were loaded on Factor one and not on Factor two, as they had erroneously interpreted earlier (Factor two was hazardous exposures).

This error is corrected by re-running all analyses using the correct factor (physical work load). The authors re-conducted the analyses and found only minor differences compared with the original figures given, and it was also found that the error did not alter the conclusions drawn.

The following corrections should be incorporated into any future analysis of the original article:

In Results section, under Abstract, Age and sex-adjusted HR varied from 1.18 to 1.54, instead of 1.66. In addition, the last sentence of the Results in Abstract (Decreased physical work load was associated with lower risk of antidepressant and anxiolytic medications) should be deleted.

In Results section, under the main text, the following should be corrected:

Paragraph 2: "The association between repeated high physical work load and any psychotropic medication was also statistically significant (HR=1.27, 95% CI: 1.08 to 1.49)." rather than "The association between repeated high physical work load and any psychotropic medication was marginally statistically significant (HR=1.17, 95% CI: 0.98 to 1.39)."

Paragraph 3: "repeated high physical work load HR=1.54 (95% CI: 1.15 to 2.06)" instead of "HR=1.66 (95% CI: 1.24 to 2.23)." In addition, "Increased job control and physical work load were associated with subsequent sedative and hypnotic medication." should read "Increased job control was associated with subsequent sedative and hypnotic medication."

Paragraph 4: The last sentence "Compared with repeatedly high physical work load, decreased physical work load was associated with a lower risk of subsequent antidepressant and anxiolytic medication" should be deleted.

In Discussion, paragraph 6 should have HR=1.54 instead of HR=1.66.

The review led also the three tables, figure 3 and online appendix 2 to be slightly revised. The revised tables are available with this article as tables 1, 2 and 3, figure 3, and appendix 2. The revised figures in tables have been highlighted in red.

Table 1 Distribution of demographics (Phase 1; 2000–2002), working conditions (Phase 1 – Phase 2; 2007) and any psychotropic medication* between Phase 2 and 2013, the Helsinki Health Study, Finland (%) (n=3587)

	No medication N (%)	Medication N (%)	Mean DDDs (SD)†
Sex			
Women	2034 (71)	847 (29)	496.0 (773.3)
Men	545 (77)	161 (23)	487.1 (793.0)
Age			
40	632 (72)	247 (28)	587.5 (949.9)
45	636 (68)	298 (32)	537.6 (788.6)
50	664 (72)	259 (28)	429.5 (660.0)
55	627 (76)	196 (24)	391.2 (627.2)
60	20 (71)	8 (29)	662.1 (818.6)
Job control			
High-High	1075 (73)	402 (27)	453.2 (749.3)
High-Low	358 (71)	148 (29)	458.3 (761.1)
Low-High	300 (72)	117 (28)	541.5 (793.9)
Low-Low	846 (71)	341 (29)	543.1 (806.6)
Job demands			
Low-Low	884 (74)	304 (26)	411.6 (647.4)
Low-High	419 (72)	165 (28)	476.1 (716.0)
High-Low	432 (72)	169 (28)	463.7 (694.2)
High-High	844 (70)	370 (30)	585.1 (915.3)
Physical work load			
Low-Low	1763 (73)	644 (27)	465.4 (728.0)
Low-High	222 (70)	93 (30)	539.6 (798.4)
High-Low	222 (71)	86 (29)	588.1 (997.3)
High-High	382 (67)	185 (33)	530.0 (810.5)

*Participants with psychotropic medication purchases in 3 months preceding Phase 2 were excluded.

†Mean of defined daily doses (DDDs) and their standard deviations (SDs) in those who had psychotropic medication purchases during follow-up.

Table 2 Age and sex adjusted hazard ratios (HRs) and their 95% confidence intervals (95% CIs) for associations of changes in working conditions between Phase 1 (2000–2002) and Phase 2 (2007) and subsequent psychotropic medication between Phase 2 and the end of 2013, the Helsinki Health Study, Finland

	Any psychotropic (n=3587)			Antidepressants (N06A) (n=3660)			Anxiolytics (N05B) (n=3867)			Sedatives and hypnotics (N05C) (n=3808)		
	N (cases)	HR	95% CI	N (cases)	HR	95% CI	N (cases)	HR	95% CI	N (cases)	HR	95% CI
Job control												
High-High	1477 (402)	1.00	Reference	1499 (264)	1.00	Reference	1573 (102)	1.00	Reference	1559 (245)	1.00	Reference
High-Low	506 (148)	1.08	0.90 to 1.31	518 (95)	1.04	0.82 to 1.32	542 (43)	1.22	0.86 to 1.74	532 (94)	1.13	0.89 to 1.43
Low-High	417 (117)	1.03	0.84 to 1.27	425 (80)	1.06	0.83 to 1.36	457 (27)	0.90	0.59 to 1.38	449 (91)	1.33	1.04 to 1.69
Low-Low	1187 (341)	1.08	0.94 to 1.25	1218 (244)	1.18	0.99 to 1.41	1295 (113)	1.37	1.05 to 1.79	1268 (205)	1.03	0.86 to 1.24

	Any psychotropic (n=3587)			Antidepressants (N06A) (n=3660)			Anxiolytics (N05B) (n=3867)			Sedatives and hypnotics (N05C) (n=3808)		
	N (cases)	HR	95% CI	N (cases)	HR	95% CI	N (cases)	HR	95% CI	N (cases)	HR	95% CI
Job demands												
Low-Low	1188 (304)	1.00	Reference	1208 (205)	1.00	Reference	1267 (83)	1.00	Reference	1254 (185)	1.00	Reference
Low-High	584 (165)	1.09	0.90 to 1.32	598 (117)	1.10	0.88 to 1.38	632 (45)	1.05	0.73 to 1.52	619 (108)	1.20	0.94 to 1.52
High-Low	601 (169)	1.09	0.91 to 1.32	610 (106)	1.01	0.80 to 1.27	649 (41)	0.96	0.66 to 1.39	639 (110)	1.16	0.92 to 1.47
High-High	1214 (370)	1.22	1.04 to 1.42	1244 (255)	1.20	1.00 to 1.45	1319 (116)	1.33	1.00 to 1.76	1296 (232)	1.21	0.99 to 1.47
Physical work load												
Low-Low	2407 (644)	1.00	Reference	2451 (427)	1.00	Reference	2575 (170)	1.00	Reference	2546 (412)	1.00	Reference
Low-High	315 (93)	1.13	0.91 to 1.41	322 (66)	1.22	0.94 to 1.58	341 (23)	1.04	0.67 to 1.60	337 (58)	1.07	0.82 to 1.41
High-Low	298 (86)	1.09	0.87 to 1.37	305 (62)	1.17	0.90 to 1.52	333 (30)	1.39	0.94 to 2.05	323 (50)	0.95	0.71 to 1.28
High-High	567 (185)	1.27	1.08 to 1.49	582 (128)	1.30	1.07 to 1.59	618 (62)	1.54	1.15 to 2.06	602 (115)	1.20	0.97 to 1.47

Participants with psychotropic medication purchases in question (the medication groups were not mutually exclusive) in 3 months preceding Phase 2 were excluded.


Table 3 Age and sex adjusted hazard ratios (HRs) and their 95% confidence intervals (95% CIs) for associations of changes in working conditions between Phase 1 (2000–2002) and Phase 2 (2007) and subsequent psychotropic medication between Phase 2 and the end of 2013, the Helsinki Health Study, Finland

	Any psychotropic (n=3587)			Antidepressants (N06A) (n=3660)			Anxiolytics (N05B) (n=3867)			Sedatives and hypnotics (N05C) (n=3808)		
	N (cases)	HR	95% CI	N (cases)	HR	95% CI	N (cases)	HR	95% CI	N (cases)	HR	95% CI
Job control												
High-High	1477 (402)	0.92	0.80 to 1.07	1499 (264)	0.85	0.71 to 1.01	1573 (102)	0.73	0.56 to 0.96	1559 (245)	0.97	0.81 to 1.17
High-Low	506 (148)	1.00	0.82 to 1.21	518 (95)	0.88	0.70 to 1.12	542 (43)	0.89	0.63 to 1.27	532 (94)	1.09	0.86 to 1.40
Low-High	417 (117)	0.95	0.77 to 1.18	425 (80)	0.90	0.70 to 1.16	457 (27)	0.66	0.43 to 1.00	449 (91)	1.29	1.00 to 1.65
Low-Low	1187 (341)	1.00	Reference	1218 (244)	1.00	Reference	1295 (113)	1.00	Reference	1268 (205)	1.00	Reference
Job demands												
Low-Low	1188 (304)	0.82	0.71 to 0.96	1208 (205)	0.83	0.69 to 1.00	1267 (83)	0.75	0.57 to 1.00	1254 (185)	0.83	0.68 to 1.01
Low-High	584 (165)	0.90	0.75 to 1.08	598 (117)	0.91	0.73 to 1.14	632 (45)	0.79	0.56 to 1.12	619 (108)	0.99	0.79 to 1.25
High-Low	601 (169)	0.90	0.75 to 1.08	610 (106)	0.84	0.67 to 1.05	649 (41)	0.72	0.50 to 1.03	639 (110)	0.96	0.77 to 1.21
High-High	1214 (370)	1.00	Reference	1244 (255)	1.00	Reference	1319 (116)	1.00	Reference	1296 (232)	1.00	Reference
Physical work load												
Low-Low	2407 (644)	0.79	0.67 to 0.93	2451 (427)	0.77	0.63 to 0.94	2575 (170)	0.65	0.49 to 0.87	2546 (412)	0.84	0.68 to 1.03
Low-High	315 (93)	0.89	0.70 to 1.15	322 (66)	0.94	0.70 to 1.26	341 (23)	0.67	0.42 to 1.08	337 (58)	0.90	0.65 to 1.23
High-Low	298 (86)	0.86	0.67 to 1.12	305 (62)	0.90	0.66 to 1.21	333 (30)	0.90	0.58 to 1.40	323 (50)	0.80	0.57 to 1.11
High-High	567 (185)	1.00	Reference	582 (128)	1.00	Reference	618 (62)	1.00	Reference	602 (115)	1.00	Reference


Any psychotropic (n=3587)			Antidepressants (N06A) (n=3660)			Anxiolytics (N05B) (n=3867)			Sedatives and hypnotics (N05C) (n=3808)		
N (cases)	HR	95% CI	N (cases)	HR	95% CI	N (cases)	HR	95% CI	N (cases)	HR	95% CI



Participants with psychotropic medication purchases in question (the medication groups were not mutually exclusive) in 3 months preceding Phase 2 were excluded.



Figure 3 Survival curves for any psychotropic medication by changes in physical working conditions.



Appendix 2 Physical working conditions - age



Appendix 2 Physical working conditions - high-high**Appendix 2** Physical working conditions - high-low

Appendix 2 Physical working conditions - low-high**Appendix 2** Physical working conditions - sex

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

BMJ Open 2019;**9**:e015573corr1. doi:10.1136/bmjopen-2016-015573corr1

